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“He drew a deep breath. 
‘Well, I’m back’, he said.” 
J. R. R. Tolkien 
 
 
 
A mia nonna, Teresina. 
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Abstract  
 
Pancreatic adenocarcinoma is the deadliest common malignancy. At the present time, it is the 
tumour causing the fourth greatest number of  deaths in the United States and has been predicted 
to become the second top cancer killer by fifteen years’ time. Despite recent advancements in 
medical treatment, the median survival for patients presenting with advanced pancreatic cancer, 
who represent approximately 75% of  all patients, is no longer than 18 months for locally advanced 
disease and 12 months for metastatic cancer.  
CA19.9 is the only approved tumour marker for pancreatic cancer. However, it is suboptimal in 
many respects, and, so as to allow optimal treatment of  all patients with pancreatic 
adenocarcinoma, new biomarkers are urgently needed. An ideal marker could be used in many 
different phases of  the management of  this disease, such as detection, monitoring of  minimal 
residual disease after resection, and assessment of  chemotherapy efficacy. 
The collection of  a tissue specimen via biopsy is, at present, essential for the diagnosis of  cancer 
and the molecular analysis of  tumour genome. Obtaining a tissue sample in pancreatic cancer is 
extremely challenging due to anatomic and clinical reasons, and up to 30% of  biopsies are 
inconclusive. 
Cell-free DNA can be isolated from plasma in a variety of  clinical scenarios. In oncologic 
patients, cancer-specific genetic alterations can be recognised in circulating DNA fragments. This 
indicates the presence of  circulating tumour DNA (ctDNA) in the bloodstream, originating from 
apoptotic or necrotic cells in the primary tumour, metastases, or in the bloodstream. The detection, 
measurement and genetic characterisation of  ctDNA may provide the clinician with a real-time 
genetic profile representative of  all tumour lesions. The mini-invasiveness of  this technique, which 
would only require a blood sample, allows serial monitoring of  tumour dynamics. This approach 
has been called the “liquid biopsy”; in contrast, the conventional tissue biopsy only provides a 
snapshot of  one tumour lesion at a single time point. 
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The presence of  mutant sequences of  the KRAS oncogene in the circulating cell-free DNA of  
a substantial proportion of  patients with pancreatic adenocarcinoma has been highlighted in some 
studies to date. Recent works in other malignancies, such as colon cancer and lung cancer, suggest 
that the analysis of  ctDNA may provide useful information as a diagnostic, predictive, and 
prognostic tumour marker. 
In our proof-of-concept study, we investigated the possible role of  ctDNA as a marker of  
response to treatment in a cohort of  patients with locally advanced and metastatic pancreatic 
adenocarcinoma. Sixty-two blood samples were collected from 24 prospectively recruited patients 
before the initiation of  chemotherapy (FOLFIRINOX or gemcitabine plus nab-paclitaxel), 15 days 
and 60 days after chemotherapy institution, and when imaging provided confirmation of  disease 
progression. Droplet Digital PCR was used to detect KRAS mutations in plasma samples. Median 
follow-up time was 6.5 months. 
Nineteen patients (79%) had detectable mutant KRAS in the baseline plasma sample. Three 
patients turned from KRAS-negative to KRAS-positive during the course of  chemotherapy; 
circulating tumour DNA was, therefore, detectable in 22 patients (91%) throughout the follow-up, 
a higher proportion than in any other previous study.  
Among the 22 patients with detectable circulating tumour DNA at any point of  the follow-up, 
20 provided more than one blood sample, thus allowing the evaluation of  ctDNA concentration 
trends as indicators of  response to treatment or progression. For 14 (70%) of  these patients, 
ctDNA trends were concordant with imaging findings at 8-12 weeks of  treatment. ctDNA levels 
remarkably declined, paralleling CA19.9 ones, in patients with partial response or stable disease. 
ctDNA increased almost four-fold in the group of  patients who did not respond to chemotherapy 
and rapidly experienced progression, while the average CA19.9 level did not rise. In the subgroup 
of  patients with disease control and concordantly downward ctDNA trend, a marked fall in ctDNA 
concentration (-91%) anticipated the radiological response by 54 days. In the group of  patients 
with disease control, ctDNA levels declined on average by almost 50% from baseline to day 15; in 
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patients encountering disease progression during the follow-up, the same value increased on 
average by 250%. 
Baseline ctDNA concentrations showed a moderate correlation with tumour burden, achieving 
a borderline level of  statistical significance (p = 0.06), with progression-free survival (p = 0.08), 
and overall survival (p = 0.06).  
Survival analysis did not show the progression-free survival to be statistically different for 
KRAS-positive and KRAS-negative patients at baseline. However, just 1 KRAS-negative patient 
(20%) experienced progression of  disease, as opposed to 11 patients (57%) in the group with 
detectable mutant KRAS at baseline. Patients with stable or declining ctDNA levels after one cycle 
of  chemotherapy had a significantly longer progression-free survival (7.2 vs. 2.6 months, p = 0.037) 
than patients with ctDNA on the rise. 
In conclusion, our findings support the hypothesis according to which ctDNA has the potential 
to become a new biomarker for the monitoring of  treatment efficacy in advanced pancreatic cancer. 
However, further research is required, as the various steps of  the procedure must be standardised 
and this methodology needs to be validated in large clinical trials.  
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Chapter 1. Pancreatic cancer 
 
1.1. Epidemiology 
“If  cancer is the emperor of  all maladies, then pancreatic adenocarcinoma is the ruthless 
dictator of  all cancers”.1 
 
Pancreatic ductal adenocarcinoma (PDAC), which represents more than 85% of  tumours arising 
from the pancreas, is the most lethal common malignancy2, with the lowest 5-year relative survival 
rate among the so-called “deadliest”, or “recalcitrant”, cancers – the subtypes which still fall under 
50% survival rate nowadays3. Out of  100 patients diagnosed with PDAC, only 6 are still alive 5 
years after diagnosis4, compared to the current average of  69 for all types of  cancer.  
The most up-to-date data5 indicate that pancreatic cancer is the eleventh most common 
malignancy newly diagnosed in males and the ninth in females. Despite its relatively low incidence, 
ranging from 1 to 10 cases for 100,000 people2, it is the fourth leading cause of  cancer-related 
deaths in both sexes at the present time (Fig. 1). The incidence of  this neoplasm shows an upward 
trend, with a +0.8%/year rate for males and +2.0%/year for females respectively5. As a result, total 
deaths due to pancreas cancer have been projected to increase dramatically in the next years, 
resulting in pancreatic and colorectal cancers causing an equivalent number of  deaths in 2020 and 
pancreatic adenocarcinoma becoming the second top cancer killer by 2030 (Fig.2)6. The estimated 
lifetime risk of developing pancreatic cancer is 1.47%; this risk increases with age, with onset 
occurring in the seventh and eighth decades most commonly4.  
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1.2. Risk factors 
The aetiology of  pancreatic cancer is complex and multifactorial; a number of  factors are known 
to increase the risk, some of  which are modifiable and some non-modifiable.  
The first category includes cigarette smoking, obesity, high animal fat intake, occupational 
exposure to nickel and chlorinated hydrocarbons, partial gastrectomy and recent-onset diabetes 
mellitus; age, race, sex, positive family history, chronic pancreatitis, and non-O blood group belong 
to the latter4.      
Cigarette smoking and family history are dominant among risk factors7. About 20% of  PDACs 
are caused by cigarette smoking: current smokers have a 2.2-fold increased risk of  pancreatic cancer 
compared to non-smokers, and the risk increases with the duration of  the smoking habit and the 
number of  cigarettes smoked8. 
It is estimated that 5 to 10% of  pancreatic cancers have an inherited component. In the majority 
of  cases, the genetic basis for familial aggregation has not been identified, but there are some 
familial syndromes which definitely confer an increased risk for the development of  a pancreatic 
neoplasm9. For example, patients with hereditary pancreatitis caused by a mutation in the PRSS1 
or SPINK1 genes, coding for trypsinogen and pancreatic secretory trypsin inhibitor respectively, 
have a 50-fold increased risk of  developing pancreatic cancer10.          
Furthermore, there are many cases in which the syndrome is caused by a mutation in a tumour 
suppressor gene, such as CDKN2A, coding for the cyclin-dependent kinase inhibitor p16 (Familial 
Atypical Multiple Mole Melanoma syndrome), MLH1, MSH2, MSH6, involved in the DNA 
mismatch repair (Hereditary Non-Polyposis Colorectal Cancer syndrome), BRCA2, which plays a 
role in DNA double-strand breaks repair (Familiar Breast Cancer 2), ATM, a protein kinase 
activated by DNA double-strand breaks and recruiting tumour suppressor proteins such as p53 
(Ataxia Telangiectasia), and STK11 (Peutz-Jeghers syndrome)9. Germline BRCA2 mutations 
account for the highest proportion of  known causes of  inherited pancreatic cancer, having been 
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identified in 5-17% of  families with familial pancreatic cancer11. 
 
1.3. Pathogenesis  
Pancreatic cancer arises as the result of  a progression cascade involving multiple mutations. As 
in the polyp-to-adenocarcinoma sequence established in colon cancer, there is a progression from 
normal ductal epithelium, to duct lesions, to invasive ductal adenocarcinoma in pancreatic lesions 
(Fig. 3)12. Three different noninvasive lesions have been identified as precursors to PDAC: 
pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasm (IPMN), 
mucinous cystic neoplasm (MCN)4,7.  
PanIN is the most frequent noninvasive precursor to invasive PDAC. PanIN formation is 
preceded by acinar-to-ductal metaplasia13. A stepwise progression from low-grade to high-grade 
dysplasia is then recognisable moving from PanIN-1A and 1B onto PanIN-2 and 3: the increase in 
cytological and architectural atypia corresponds to incremental genetic alterations, which are the 
same found in invasive pancreatic cancer13,14. More than 90% of  cases of  PanIN of  all grades have 
mutations in the KRAS oncogene: activating point mutations in KRAS codon 12, most often 
G12D, together with the overexpression of  Her-2/neu, occur early in pancreatic duct lesions with 
minimal cytological and architectural atypia (PanIN-1A and 1B). Inactivation of  the CDKN2A 
gene, coding for p16, is a feature of  the moderate dysplasia stage (PanIN-2), while the inactivation 
of  other tumour suppressors such as p53, SMAD4, and BRCA2 characterises later stages (PanIN-
3, high-grade dysplasia/carcinoma in situ)12,15. KRAS is mutated in more than 90% of  PDACs; 
CDKN2A is the most frequently altered tumour suppressor gene, with loss of  function in 
approximately 90% of  tumours; p53 is inactivated in a smaller proportion of  malignancies, around 
60-70%, and SMAD4, which mediates signaling downstream of  the transforming growth factor  
(TGF) receptor, is mutated in about 50% of  pancreatic cancers. Apart from mutations in single 
genes, pancreatic cancer is characterised by abnormalities at a chromosomal level, such as 
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amplifications, deletions, rearrangements and telomere shortening; the latter is already present in 
the early stages of  PanIN and is thought to contribute to tumour progression by enhancing 
chromosomal instability16. PanIN-1 lesions become very common with increasing age, while 
PanIN-3 is usually associated with invasive cancer7.  
PanIN lesions are too little (diameter < 5 mm) to be radiologically detected; in contrast, 
intraductal papillary mucinous neoplasms (IPMNs) are larger cystic tumours (diameter ≥ 5mm) 
which are more and more often being diagnosed because of  the advances in pancreatic imaging17,18. 
Just as Pan-INs, non-invasive IPMNs are classified as either low-grade, intermediate-grade, or high-
grade dysplasia (carcinoma in situ). Although IPMNs are only responsible for less than 15% of  
invasive PDACs, they offer the rare chance to identify a premalignant pancreatic lesion4 and either 
resect it immediately or follow it up, still being able to cure any early invasive malignancy that may 
develop. Neoplasms arising from the main pancreatic duct (MD-IPMN) and from branch ducts 
(BD-IPMN) have a different risk of  evolving into invasive PDAC: 40-92% for MD-IPMN, which 
should always be resected if  the patient is deemed fit for surgery, compared to 15-25% for BD-
IPMN. The latter may qualify for upfront resection or be managed via surveillance by periodic 
pancreatic imaging after radiological and histological evaluation depending on the risk stratification 
category they belong to (high risk, worrisome risk, low risk) according to the latest guidelines19. 
Like PanINs, IPMNs frequently harbour KRAS mutations (40-65%); in contrast, IPMNs hardly 
ever inactivate SMAD4. Moreover, 40 to 80% have activating mutations in the GNAS gene, coding 
for the G-protein subunit αs, which activates adenylate cyclase to produce cyclic AMP
2,7.  
Unlike PanIN and IPMN, mucinous cystic neoplasms (MCNs) do not communicate with 
pancreatic ducts. This kind of  lesion is a less common precursor to pancreatic cancer made of  
mucin-producing epithelial cells and an associated ovarian-type stroma, is typical of  women and 
has an associated invasive carcinoma in about one-third of  cases4. 
As the most common oncogenic mutation in both premalignant precursors and PDAC (present 
in more than 90% of  invasive tumours), KRAS activation has been the object of  in-depth 
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investigation. The KRAS gene encodes a GTPase of  the Ras family which, if  activated, can recruit 
and activate proteins in the signal transduction pathways originating from growth factors’ and other 
ligands’ receptors, such as c-Raf  and PI 3-kinase20. KRAS is a major driver of  pancreatic 
tumorigenesis, contributing to cancer initiation by inhibiting the entrance of  cells into a state of  
permanent growth arrest21 and enhancing cell growth and reproduction (Fig. 4), while cancer 
progression requires the inactivation of  tumour suppressor genes, which occurs at later stages. A 
high level of  sustained activity of  the oncogenic form of  KRAS (e.g. KRASG12D) is necessary for 
earlier lesions to develop into pancreatic cancer. In a genetically engineered mouse model in which 
the mutant KRAS allele may be switched off  at will, stopping KRAS activity causes massive cell 
death and proliferation arrest, with rapid tumour regression.  
Moreover, KRAS regulates factors which play a role in the relationship between the malignant 
cells and the stroma, such as sonic hedgehog, interleukin-6 (IL-6) and prostaglandin E. Pancreatic 
ductal adenocarcinoma is associated with a desmoplastic stromal reaction: intratumoral connective 
tissue surrounding the cancer cells increases considerably, preventing chemotherapeutic drugs from 
penetrating into the cancer tissue. Sonic hedgehog signalling regulates the desmoplastic reaction of  
the stroma. In particular, pancreatic cancer cells closely interact with activated pancreatic stellate 
cells (PaSCs) for the latter to produce extracellular matrix and cause stromal fibrosis. Conversely, 
PaSCs enhance cancer cells proliferation and inhibit apoptosis and are believed to be at least 
partially responsible for the resistance of  this malignancy to chemotherapy and radiotherapy22–24. 
This dense fibrosis is a hypovascular and hypoxic microenvironment the tumoural cell adapts to by 
shifting from aerobic metabolism to anaerobic glycolysis, a process which is in turn regulated by 
KRAS. Macropinocytosis and autophagy are enhanced, too, and this is another mechanism through 
which this oncogene guarantees the supply of  metabolites to malignant cells (Fig. 4)20,25.   
Inflammatory markers such as IL-6 are increased in PDAC patients. The main sources of  this 
cytokine are tumour-associated macrophages. Even though only a small minority of  individuals 
diagnosed with pancreatic cancer have clinical evidence of  chronic pancreatitis, there is histological 
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evidence of  inflammation in tissue specimens, thus suggesting a possible injury-inflammation-
cancer pathway26. The inflammatory stimulus activates PaSCs, which in turn recruit inflammatory 
cells such as neutrophils, macrophages and T cells, which produce IL-6; a possible effect of  the 
inflammatory microenvironment on cancer progression is that IL-6 activates STAT-3 to promote 
the development of  PanIN and PDAC. 
 
1.4. Clinical presentation 
Molecular genetics studies have shown that cancer progression in PDAC takes at least a decade 
from the initiating mutation to invasive carcinoma. At least five additional years are necessary for 
a clone with metastatic potential to emerge within the primary tumour27, thus providing an 
extended time window in which the tumour could be identified before spreading to other organs. 
However, one of  the reasons why the prognosis of  pancreatic cancer is so dismal, alongside its 
chemo- and radioresistance, is that diagnosis usually occurs at a late stage. Patients usually remain 
asymptomatic or have subtle and non-specific symptoms until the tumour invades surrounding 
structures28. The most common symptoms related to pancreatic cancer are asthenia (86% of  
patients), anorexia (83%), unexplained weight loss (85%), diffuse abdominal pain (79%), epigastric 
pain (71%), mid-back pain (49%), choluria (59%), jaundice (51%) (Table 1). Physical examination 
can reveal, apart from the above-mentioned jaundice, hepatomegaly (39%), a mass in the abdominal 
right upper quadrant (15%), ascites (5%), positive Courvoisier’s sign (palpable distended gallbladder 
at the right costal margin; 13%) and Trousseau’s sign of  malignancy (recurrent migratory 
thrombophlebitis; 3%) (Table 1)29.   
The location of  the mass within the pancreas influences how and how rapidly the tumour will 
manifest itself  (Fig. 5). Neoplasms arising from the head, neck or uncinate process, which account 
for more than 60% of  pancreatic malignancies, usually have an earlier presentation as a 
consequence of  compression or infiltration of  the common bile duct and consequent sudden-
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onset obstructive jaundice28. The other two complaints that form the classic triad of  signs and 
symptoms derived from a malignancy in the head of  the pancreas are weight loss and abdominal 
pain. Weight loss can be due to various motives such as anorexia, maldigestion from pancreatic 
duct obstruction, and cachexia. Pain is usually referred to the epigastrium or right hypochondrium, 
with radiation to the sides and/or back and worsening after food intake29. Cephalic tumours can 
infiltrate the duodenum, causing gastric outlet obstruction or delayed stomach emptying, with 
associated nausea and early satiety.  
In one-fifth to one-quarter of  cases the lesion is located in the body or tail of  the pancreas, left 
of  the superior mesenteric vessels, and its primary manifestations are weight loss and pain. The 
latter arises when the tumour has reached considerable dimensions or has spread beyond the 
pancreas, for example to the peri-neuronal tissue or ganglia themselves. The pain has an insidious 
onset, with a gnawing visceral quality, is usually referred to the back and, with regard to its intensity, 
is severe. The duration of  symptoms is usually of  several months before diagnosis, compared to 
days or weeks for tumours of  the head4. 
Up to 10% of  patients with PDAC present with new-onset diabetes or worsening of  pre-existing 
diabetes: the relationship between diabetes mellitus and pancreatic cancer is complex and 
controversial. In several studies, the prevalence of  diabetes in PDAC has been reported to be 
between 40 and 75%30–32. Diabetic subjects have been found to have a 30% higher risk of  pancreatic 
cancer persisting for more than 20 years after the initial diagnosis of  diabetes, suggesting that 
diabetes is not merely a marker of  pancreatic dysfunction as a result of  neoplasia33,34. The cause of  
the diabetogenic state is still not well understood, but diabetes is sometimes cured by resection of  
the tumour, thus suggesting that it is indeed caused by the neoplasm itself35. This kind of  diabetes 
would be classified as type 3c, pancreatogenous diabetes, as opposed to the more common type 2 
late-onset diabetes. Patients aged over 50 with new-onset diabetes have an 8-fold higher risk of  
developing pancreatic cancer within 3 years of  the diagnosis compared to the general 
population35,36: as a result, any of  the above-mentioned symptoms in the presence of  late-onset 
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diabetes should strongly alert the clinician to the possibility of  a malignancy arising from the 
pancreas. However, most patients with newly diagnosed late-onset diabetes do not have pancreatic 
cancer and, apart from weight loss, few clinical clues exist to suspect this deadly underlying 
condition in a patient who has recently received a diabetes diagnosis31,35.  
With regard to the differential diagnosis of  pancreatic cancer, choledocholithiasis, pancreatic 
pseudocysts, chronic pancreatitis, biliary tract and ampullary carcinomas, and other pancreatic 
malignancies such as pancreatic lymphoma must be ruled out28. 
PDAC is usually diagnosed at a late stage; diagnoses posed at an early stage are rare and usually 
occur for small tumours located in the head near the common bile duct which is thereby occluded, 
causing jaundice, or are incidental, following abdominal imaging performed for other reasons. 
 
1.5. Diagnosis  
Diagnosis and staging of pancreatic cancer come together with the necessity to evaluate the 
possibility of  surgical resection, this being the only chance of  cure.  
Diagnostic certainty is gained only through histological examination of  a tissue sample. In the 
case of  non-resectable advanced disease, histopathological diagnosis must be obtained before 
starting medical treatment. In case clinical and radiological features make highly likely the presence 
of  a resectable malignancy, pre-surgery histological diagnosis is not mandatory. Endoscopic 
ultrasonography-guided fine-needle aspiration (EUS-FNA) biopsy has a high diagnostic accuracy 
(85-90%) for pancreatic cancer33. Alternatively, a tissue specimen can be obtained via CT- or US-
guided percutaneous biopsy. 
A number of  different imaging techniques have been evaluated to pose a diagnosis and stage 
the disease (Fig. 6)37, while also playing a role in monitoring the response to chemotherapy: 
 Abdominal ultrasound (AUS) is usually the first-line imaging technique used when 
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approaching a patient with clinical suspicion of  pancreatic cancer, especially when jaundice 
is the main sign at presentation. However, the diagnostic accuracy of  ultrasonography 
greatly depends on the operator’s experience and the patient’s condition in terms of  obesity 
and bowel gas, thus limiting its adoption for staging and assessing resectability. The 
sensitivity and specificity of  transabdominal ultrasound for pancreatic cancer range from 
75% to 89% and from 90% to 99% respectively38. The involvement of  the major vessels 
can be assessed coupling standard AUS with a Doppler ultrasound study39. 
 Multidetector-row computed tomography (MDCT) with contrast medium is at the 
present time the imaging technique routinely used for the radiological diagnosis of  
suspicious pancreatic lesions (e.g. an hypoechoic lesion found on AUS previously 
performed), assessment of  vascular invasion and resectability, and diagnosis of  
metastases40. Pre-contrast scans can show calcifications in the pancreas, thus playing a role 
in differential diagnosis by ruling in chronic pancreatitis. The vascular-poor and hypo-
perfused pancreatic tumour enhances poorly compared to the surrounding parenchyma in 
the arterial phase, resulting in the lesion being visualised as a hypoattenuating area, and 
gradually enhances with delayed images. The arterial phase images also allow the assessment 
of  arterial vessels involvement, while the venous phase images are used to identify 
peritoneal foci and liver metastases37. Hypoattenuation has a sensitivity of  75% and 
specificity of  84% in diagnosing pancreatic cancer; other helpful CT findings are pancreatic 
and common bile duct dilatation, ductal interruption, distal pancreatic atrophy, pancreatic 
contour abnormalities41. Overall, MDCT has an accuracy of  roughly 90% for diagnosis and 
an accuracy of  about 85% in determining resectability42,43. 
 Gadolinium-enhanced magnetic resonance imaging (MRI) has been shown to be 
non-inferior to MDCT, being their sensitivity (83-85% vs. 83%) and specificity (63% vs. 
63-75%) similar44. MRI is particularly useful to assess peri-pancreatic infiltration, due to the 
high contrast resolution of  this technique to differentiate pancreatic parenchyma and the 
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surrounding fat. Magnetic resonance cholangiopancreatography (MRCP) is frequently 
performed in conjunction with abdominal MRI, does not need intravenous contrast and 
allows non-invasive delineation of  the pancreatic duct and biliary tract45. It is used for the 
diagnosis of  small pancreatic masses and is gradually replacing the invasive endoscopic 
retrograde cholangiopancreatography (ERCP), although MRCP does not allow tissue 
sampling. 
 ERCP is a sensitive tool to visualise the biliary tract and pancreatic duct, with 
sensitivity and specificity of  92% and 96% respectively for diagnosing pancreatic cancer. 
Tissue samples may be collected through forceps biopsy or brush cytology. Its diagnostic 
role has been decreasing lately because of  the 5-10% risk of  significant complications, such 
as acute pancreatitis and gastrointestinal or biliary perforation, and the availability of  safer 
alternatives such as MRCP. ERCP is currently mainly used to insert a plastic or metal biliary 
stent for palliation of  jaundice and pruritus due to tumour obstruction of  the common 
bile duct.  
 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) has several 
limitations in diagnosing pancreatic carcinoma, including possible false-negative results in 
hyperglycaemia and possible false-positive results in pancreatitis. Two meta-analyses 
showed that 18FDG-PET plus CT has no major advantages over routine methods46,47. 
However, it can prove useful in other settings, i.e. confirming a complete remission or 
differentiate post-surgical scar tissue and local recurrence.  
 Endoscopic ultrasonography (EUS) has been reported to be superior to MDCT in 
diagnosing pancreatic cancer, with a sensitivity of  98-100% compared to about 85% for 
MDCT48,49. This invasive procedure requires the introduction of  an endoscope in the upper 
digestive tract; the endoscope is equipped with a high-frequency ultrasound transducer 
which allows high-resolution imaging of  the pancreas and surrounding blood vessels. 
Tissue sampling for diagnostic cytology/histology can be undertaken at the time of  the 
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endoscopic ultrasound (EUS-FNA). EUS is highly operator-dependent and requires 
expensive equipment; therefore, the use of  this method is still not widespread.  
A role in the diagnosis of  PDAC is also played by serum tumour markers. The most useful and 
widely adopted is the cancer-associated antigen 19.9 (CA19.9), an epitope of  blood group Sialis 
Lewis antigen. When used in patients with clinically- and radiologically-based suspicion for 
pancreatic cancer, CA 19.9 serum levels have a sensitivity and specificity for diagnosis ranging from 
79% to 81% and from 82% to 90% respectively50. However, CA19.9 is not useful as a screening 
marker because of  low positive predictive value, which is below 1%. The sensitivity is limited for 
small-sized tumours, while it is positive in about 80% of  cases of  advanced pancreatic cancer. 
CA19.9 is falsely increased in a number of  pancreaticobiliary disorders, most commonly 
obstructive jaundice50, given the fact that CA19.9 is partly excreted through bile, but also in acute 
and chronic pancreatitis and pancreatic pseudocyst. A preoperative CA19.9 value >100 U/mL 
implies likely locally advanced or metastatic disease, while a concentration of  <100 U/mL suggests 
a resectable tumour50. Also, a preoperative CA19.9 level > 100 U/ml has been shown to be a 
predictor of  early recurrence and poor prognosis after surgical resection51. A drop in postoperative 
CA19.9 serum levels by at least ≥20-50% from baseline following surgical resection or 
chemotherapy is associated with longer survival50. In patients with CA19.9 elevation, this marker 
may be used as a predictor of  prognosis, overall survival, and in monitoring the response to surgical 
and medical treatment; as a result, it is advisable to measure CA19.9 serum levels before surgery, 
before the start of  adjuvant chemotherapy and during follow-up52. 
 
1.6. Staging 
Unlike many other malignancies, imaging is the primary means through which the stage of  
pancreatic cancer is determined53. Definite pathological staging is possible only after surgical 
resection, which, however, cannot be performed in about 80% of  cases. As a result, pancreatic 
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cancer is often staged by clinical rather than formal TNM classification. Abdominal helical CT 
scans and chest X-rays (or chest-abdomen-pelvis CT) are the radiological bases of  staging, given 
the fact that pancreatic cancer most often metastasises to the liver, abdomen, and lungs2,4. 
According to the American Joint Committee on Cancer Tumour-Node-Metastasis classification 
(Table 2), potentially resectable tumours are classified as T1-T3, whereas T4 tumours, which involve 
the superior mesenteric artery (SMA) or celiac axis, are unresectable54. Masses involving the 
superior mesenteric vein (SMV), portal vein (PV) or splenic vein are classified as T3 because veins 
are possibly susceptible of  resection and reconstruction. Resectable tumours without lymph node 
metastases belong to stage I and IIA; resectable tumours which have metastasised to regional lymph 
nodes (N1) are classified as stage IIB, while stage III is composed of  unresectable, locally advanced 
pancreatic cancers (LAPC). Metastatic disease (stage IV) includes both cases of  radiological or 
histological evidence of  metastasis to distant organs such as liver, lungs etc. and positive peritoneal 
washing cytology.   
The other main staging system is the one which follows the guidelines released by the National 
Comprehensive Cancer Network: pancreatic cancers form a continuum from resectable to 
unresectable according to the involvement of  nearby structures and the presence or absence of  
distant metastases (Fig. 7)55. The direct reference to surgical intervention is because margin-negative 
surgical resection is the only opportunity to cure pancreatic adenocarcinoma and therefore accurate 
determination of  resectability is of  momentous importance for optimal management. 
Locoregional disease can be divided into three categories: resectable, borderline resectable, and 
locally advanced (unresectable), according to the extent of  local invasion. Patients with borderline 
resectable disease initially may not be operable, but, with some cytoreduction (e.g. neoadjuvant 
chemotherapy or chemoradiotherapy) may achieve a margin-negative resection55. 
Cases in which there is no evidence of  distant metastases and tumour extension to the SMV 
and PV and there are clear fat planes around the celiac axis, the hepatic artery, and SMA should be 
categorised as having localised resectable disease (Table 4). Radiographic findings definitely 
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contraindicating surgery include distant metastases, major venous thrombosis of  the PV or SMV 
extending for several centimetres, and circumferential encasement of  the SMA, celiac axis or 
proximal hepatic artery56. 
There is no general consensus on the definition of  borderline resectable pancreatic cancer 
(BRPC). In 2014, the NCCN Pancreatic Adenocarcinoma Panel declared that “no perfect definition 
of  borderline resectable disease is currently possible because of  insufficient data”55. However, 
according to the latest NCCN criteria, BRPC is defined by radiological findings of  venous 
involvement of  the SMV or PV with vein distortion or narrowing, or occlusion of  the vein with 
suitable proximal and distal vessel allowing for safe resection and replacement55. In fact, the 
involvement of  a short segment of  PV or SMV permits successful resections thanks to venous 
reconstruction57, while longer segment involvement or occlusion at the SMV-PV confluence make 
resection technically prohibitive. As for arterial involvement, BRPC can be characterised by 
radiological evidence of  encasement of  a short segment of  the hepatic artery, without evidence of  
tumour extension to the celiac trunk, and/or tumour abutment of  the SMA involving 180° or less 
of  the artery circumference (Table 4)55. Other authors define BRPC as (1) tumour abutment 
(≤180°) of  the SMA or celiac artery, (2) encasement (>180°) of  the SMV and/or PV with an 
option for venous resection/reconstruction, (3) presence of  indeterminate liver/lung lesions, 
regional lymph node metastases, or a patient with a performance status deemed ineligible for 
immediate surgery58. 
Only 10 to 20% of  patients can be classified as resectable (stage I-II) at diagnosis59, while 
approximately 5-7% as borderline resectable60. Among those who undergo surgical resection and 
have tumour-free R0 margins, the 5-year survival rate is still very low, ranging between 10 and 25%, 
with a median survival of  20-23 months59. 
One-quarter to one-third of  cases fall within the locally advanced tumour category (stage III), 
which is associated with a median survival of  8 to 14 months, with most of  the patients progressing 
to metastatic disease within the first year. 
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The remaining 45-55% of  subjects present with metastatic disease (stage IV), for which the 
prognosis is still extremely dismal, with a median life expectancy inferior to one year from 
diagnosis4,7 (Table 3).   
 
1.7. Management 
Patients with pancreatic cancer need to be managed by a multidisciplinary team including 
medical and radiation oncologists, surgeons, radiologists, pathologists, pain management specialists, 
dieticians and, in the terminal stages, palliative care experts61. 
 
1.7.1. Surgical management of  resectable tumours 
When the tumour is resectable, surgery remains the treatment of  choice, although pancreatic 
cancer is a systemic disease at the time of  diagnosis and there is preliminary evidence that patients 
may so benefit from neoadjuvant or peri-operative medical treatment62,63. Surgery is presently the 
only potentially curative intervention and can result in significantly longer survival compared with 
other treatment options33. Patients who undergo surgery with negative margins and subsequently 
receive adjuvant therapy have the best chance of  cure. However, outcomes are still far from 
optimal: even after multimodality treatment including surgical resection, 5-year survival rates only 
reach 25 to 30% at best64.  
The primary goal of  surgery is to obtain the total removal of  the tumour, identified by resection 
margins negative for cancer cells. The Union for International Cancer Control (UICC) and the 
American Joint Committee on Cancer (AJCC) classify possible pathological findings after surgery 
as negative resection margins (R0), microscopic tumour infiltration (R1) and macroscopic residual 
tumour (R2). American guidelines define microscopic residual tumour as the presence of  cancer 
cells at the surface of  the resection margin (0 mm rule), whereas the British Royal College of  
Pathology (RCPath) define R1 as the presence of  malignant cells within 1 mm of  the resection 
  
21 
margin (1 mm rule)65. The International Study Group of  Pancreatic Surgery (ISGPS) has recently 
recommended adhering to the latter33, as there is evidence that a minimum clearance of  more than 
1 mm is required for effective disease control, as survival after resection with less than 1-mm 
margin (R0-close resection) is worse than that of  resection with more than 1-mm margin (R0-wide 
resection) and similar to survival after R1 resection66. 
The assessment of  resectability by radiological evaluation of  the extent of  local invasion and, 
in particular, vessel involvement, is of  critical importance to select the patients with a high 
probability of  achieving R0 resection, who are the ones eligible for immediate surgery; nonetheless, 
R1 resection is a postoperative finding in about 30% of  patients. Subjects with BRPC have a high 
likelihood of  R1 resection and, as a consequence, should not be regarded as good candidates for 
upfront surgery67.  
The location of  the malignancy influences the type of  surgery which will be performed. Surgical 
techniques for pancreatic cancer include pancreatoduodenectomy (Whipple procedure) for 
tumours located in the uncinate process or head of  the pancreas, distal pancreatectomy with 
splenectomy for lesions in the body or tail of  the pancreas, and total pancreatectomy for those 
tumours which diffusely involve the gland28. Laparoscopy has been shown to reduce the morbidity 
associated with distal pancreatectomy without negative oncologic outcomes68,69 and is, therefore, a 
viable approach for selected lesions in the tail of  the pancreas; however, there is still insufficient 
evidence to recommend it and conventional open surgery remains the standard of  care at the 
present time67. Frequent postoperative complications are pancreatic anastomosis leaks and delayed 
gastric emptying: research has been conducted on which operative approaches (e.g. pylorus-
preserving, subtotal stomach-preserving) have the least likelihood of  complications after 
pancreatoduodenectomy, but such studies have found no clear advantage of  one technique over 
another7.   
The hospital volume has been found to be associated with risk of  complications, mortality, 
length of  hospital stay, margin status, and survival70,71: as a result, surgery for pancreatic cancer 
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should be carried out in dedicated centres performing an adequate number (>15-20) of  pancreatic 
resections per year67. 
Resection of  the SMV or PV to achieve macroscopic tumour clearance can be performed safely 
with acceptable operative morbidity and mortality72,73. Instead, arterial resections are associated 
with increased morbidity and mortality and are not recommended67, although some surgeons with 
great expertise in the field of  vascular reconstruction consider them feasible. 
Lymph node involvement represents a major prognostic factor. Therefore, standard 
lymphadenectomy must be performed during surgery ensuring that an appropriate number (at least 
12-15) of  regional lymph nodes are collected. The total number of  lymph nodes analysed, the 
number of  metastatic lymph nodes, and the ratio between them (lymph node ratio) should be 
reported, as this is one of  the most significant prognostic parameters74,75.  
In fact, other factors suggesting a poor prognosis with early recurrence and mortality include 
high tumour grade (G3-G4), a large size tumour, high (>200 U/ml) preoperative CA19.9 levels, 
persistently elevated postoperative CA19.9 levels, R1 or R2 resection76. In contrast, outcomes are 
more favourable if  the tumour is relatively small (<3 cm), well differentiated (G1-G2) and has not 
metastatised to lymph nodes (N0)28.  
Nevertheless, it should be noted that, even under optimal conditions, the median survival of  
patients who undergo surgical resection for PDAC only is less than 20 months and the 5-year 
survival rate is about 10%61, thus advocating for the need of  subsequent additional treatment. This 
is because, unfortunately, development of  distant metastases, most frequently to the liver, and local 
recurrence are extremely common. 
 
1.7.2. Adjuvant treatment for patients with surgically resected pancreatic cancer  
A number of  studies have evaluated which chemotherapy and chemoradiation (CRT) regimens 
could be deemed appropriate for adjuvant treatment.  
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In the European Study group for Pancreatic Cancer 1 (ESPAC-1) trial, a two-by-two factorial 
design study, patients who underwent macroscopically radical resection (R0 or R1) were 
randomised in four treatment arms: chemotherapy (5-fluorouracil and folinic acid), CRT (20 Gy 
over a two-week period plus 5-fluorouracil), both, or observation only59. The results indicated that 
patients receiving adjuvant chemotherapy had a better 5-year survival rate (21% vs. 8%) and median 
survival (20.1 vs. 15.5 months), thus demonstrating a clear survival benefit for chemotherapy, 
irrespective of  whether the patient had received CRT or not, and reinforcing the hypothesis that, 
being pancreatic cancer a systemic disease at the time of  diagnosis, it needs an effective systemic 
treatment. Worrisomely, patients treated with CRT, alone or associated with systemic 
chemotherapy, had a worse outcome, the 5-year survival rate being 10% for patients who received 
CRT and 20% for those who did not and the median survival respectively 15.9 and 17.9 months 
(p=0.05). The authors claimed that CRT delayed the start of  systemic chemotherapy, thus reducing 
the benefit deriving from its administration as soon as possible after surgery; these data, albeit 
criticised for study design issues, have brought to a fall in the use of  adjuvant chemoradiation in 
Europe. 
The Charité Onkologie 001 (CONKO-001) study was a randomised controlled trial whose 
purpose was to compare adjuvant gemcitabine with no postoperative medical treatment after 
curative-intent resection of  pancreatic cancer77. Gemcitabine had been introduced as the standard 
first-line treatment in metastatic PDAC in the late 1990s, with both a significant rise in survival and 
an excellent safety profile, with a low incidence of  grade 3 and 4 toxicities78. In the CONKO-001 
trial, gemcitabine was administered for 6 cycles, every cycle consisting of  3 weekly intravenous 
infusions of  gemcitabine 1000mg/m2 followed by a 1-week pause. The results of  the qualified 
analysis, from which patients with even minor protocol violations were excluded, demonstrated 
improved disease-free survival (DFS) and overall survival (OS) in the gemcitabine arm compared 
to the observation-only arm: 13.7 vs. 6.9 months (p<0.001) and 24.2 vs. 20.5 months (p=0.02) 
respectively. At 5 years, approximately twice as many patients in the gemcitabine group compared 
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to the control group were still alive (22.5 vs. 11.5%). Adjuvant gemcitabine was found to have a 
beneficial effect on DFS both in patients with R0 (13.1 vs. 7.3 months) and R1 (15.8 vs. 5.5 months) 
resections. Following this study, adjuvant chemotherapy with gemcitabine was established for the 
postoperative treatment of  PDAC. 
The ESPAC-3 trial compared the two chemotherapeutic agents which had been previously 
examined in the adjuvant treatment of  pancreatic cancer: 5-fluorouracil (5-FU) and gemcitabine. 
This was the largest adjuvant trial ever conducted, in which 1088 patients were randomised to 
receive either 6 cycles of  5-FU and folinic acid (420 mg/m2 + 20 mg/m2 for 5 consecutive days 
every 28 days) or gemcitabine (1000 mg/m2 once weekly for 3 out of  4 weeks)79. No significant 
difference in DFS (14.1 vs. 14.3 months, non-significant) and OS (23.0 vs. 23.6 months, non-
significant) were reported, but treatment-related grade 3 and 4 toxicities were more frequent in the 
5-FU plus folinic acid arm (14% vs. 7.5%). Therefore, both the American Society of  Clinical 
Oncology (ASCO) and the European Society for  Medical Oncology (ESMO) recommend either 
5-FU plus folinic acid or gemcitabine for adjuvant therapy, although the latter is usually preferred 
because less toxic61,67. It is worth noting that, as opposed to early initiation, completion of  all six 
cycles of  adjuvant chemotherapy, was reported to be a positive prognostic factor. The outcome did 
not differ if  the start of  chemotherapy was delayed up to 12 weeks after surgery; as a result, the 
start of  adjuvant treatment may be deferred until the patient has fully recovered from the major 
stress of  pancreatic surgery80.   
The Japanese Adjuvant Study group of  Pancreatic Cancer 01 (JASPAC-01) trial compared 
gemcitabine and the oral fluoropyrimidine S-1, which was developed in Japan and contains a 5-FU 
prodrug, tegafur81. The 5-year survival rate was 24.4% in the gemcitabine arm and, intriguingly, 
44.1% in the S-1 group. Since 5-FU metabolism is different in Asian and Caucasian populations, 
further research is needed to assess whether these results are valid in a non-Asian population.   
The results of  the ESPAC-4 trial have been recently presented at the ASCO 2016 Annual 
Meeting82. This trial was aimed to examine the combination chemotherapy with gemcitabine and 
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capecitabine (GEM/CAP), which had previously been found to improve the survival of  a 
subgroup of  patients with metastatic pancreatic adenocarcinoma with a good performance status 
(Karnofsky score of  90 to 100) compared to gemcitabine only83, in the adjuvant setting. Patients 
with pancreatic cancer were randomised within 12 weeks of  surgery to have either six 4-week cycles 
of  intravenous gemcitabine alone or gemcitabine plus oral capecitabine. The study had positive 
results, with a median survival for patients treated with gemcitabine plus capecitabine of  28.0 
months compared to 25.5 for gemcitabine only and a 5-year survival rate of  28.8% vs. 16.3%82. 
The results of  this trial are promising; in the future, this combination may be adopted for the 
adjuvant treatment of  the subgroup of  patients fit for polychemotherapy.  
By way of  a conclusion, at the present time, it is recommended that all patients who underwent 
surgery for PDAC and did not receive neoadjuvant treatment receive adjuvant chemotherapy with 
6 cycles of  either gemcitabine or 5-FU plus folinic acid, if  not contraindicated for medical or 
surgical reasons61,67. The use of  adjuvant chemoradiation is controversial; since its primary benefit 
is the supposed decreased risk of  local recurrence, this treatment modality may be considered for 
patients with R1 resection and/or positive lymph nodes after 4-6 cycles of  systemic adjuvant 
chemotherapy61. 
 
1.7.3. The role of  neoadjuvant therapy in borderline resectable pancreatic cancer 
In patients with BRPC, resection may be technically feasible but with a high likelihood of  
microscopically positive margins (R1 resection), this being a major negative prognostic factor for 
overall survival84.  
Neoadjuvant (preoperative) therapy has been investigated in depth as a strategy to obtain the 
downsizing and downstaging of  the mass, thus possibly allowing successful R0 resection, and better 
selection of  candidates, avoiding surgery which would very unlikely provide any clinical benefit for 
patients with particularly biologically aggressive tumours who rapidly develop distant metastases85. 
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Neoadjuvant therapy is recommended by ASCO and ESMO for the management of  BRPC; 
however, there is no consensus on which should be the standard of  care because of  the lack of  
randomised phase III studies61,67. Three meta-analyses based on phase II studies have been 
performed up to the present day. In their work published in 2010, including 111 trials and 4394 
patients with primarily resectable pancreatic cancer, BRPC and LAPC, Gillen and colleagues85 
reported an overall resection rate of  33.2% for tumours not deemed primary resectable 
(BRPC/LAPC) after neoadjuvant chemotherapy or CRT (no separate analysis for BRPC and LAPC 
was performed). Neoadjuvant chemotherapy was administered in 96.4% of  the studies considered 
(the most frequently adopted agents were gemcitabine, 5-FU, and platinum derivatives), whereas 
neoadjuvant radiotherapy was applied in 93.7% of  the trials, with doses ranging from 24 to 63 Gy. 
The median OS for patient with BRPC/LAPC who underwent resection after neoadjuvant 
treatment was 20.5 months, not significantly shorter than that of  primarily resectable patients 
treated with upfront surgery and adjuvant therapy (23.3 months). A second meta-analysis published 
in 2011 by Assifi et al.86 analysed a much smaller number of  studies: 14 phase II clinical trials. Eight 
studies used gemcitabine-based chemotherapy regimens, while the remaining 6 trials adopted 5-
FU-based regimens; patients received neoadjuvant radiotherapy in 85% of  the studies, with doses 
ranging between 30 and 50.4 Gy. The authors reported similar findings to those of  Gillen and 
collaborators: following neoadjuvant treatment, resection rate was 31.6% for BRPC/LAPC 
patients, and the median survival in resected patients was 22.3 months. Altogether, these two 
studies strongly suggest that patients who are not ideal candidates for upfront surgery because of  
the local extent of  the disease (BRPC and even LAPC) should be offered neoadjuvant therapy and 
then re-evaluated for resection85,86. Sequential treatment with induction chemotherapy aiming to 
improve the systemic control of  the disease and subsequent chemoradiation to sterilise surgical 
margins and reduce the rate of  R1 resections might be used87. At the present time, the only 
recommended CRT treatment is the combination of  radiotherapy and capecitabine, although also 
5-FU, gemcitabine or gemcitabine plus oxaliplatin have been used. 
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With regard to establishing which chemotherapy regimen should be offered for neoadjuvant 
treatment in patients with BRPC, the above-cited works are already outdated because they were 
carried out before two new regimens, FOLFIRINOX (a combination of  5-FU, folinic acid, 
irinotecan, and oxaliplatin) and gemcitabine plus nab-paclitaxel, were found to have significant 
activity in advanced pancreatic cancer (see 1.7.4, Treatment of  metastatic pancreatic cancer). These 
regimens, therefore, offer great promise as regards their adoption in patients with localised disease 
who might thus be able to undergo radical surgery and have a significantly longer survival. The 
most recent meta-analysis88, conducted by an Italian group, examined 13 trials regarding the use of  
neoadjuvant FOLFIRINOX in BRPC and LAPC: a total of  253 patients received FOLFIRINOX 
with or without radiotherapy before being re-evaluated for surgery. The rate of  resection for BRPC 
patients was 68.5%, and the percentage of  R0 resections was 69.5%. The authors, therefore, 
proposed that FOLFIRINOX could become a new standard-of-care in patients with BRPC fit for 
polychemotherapy.  
However, in the absence of  conclusive evidence from randomised clinical trials, current 
recommendations are to include patients with BRPC in clinical trials whenever possible. Otherwise, 
a sequence of  neoadjuvant chemotherapy (possible regimens: gemcitabine or FOLFIRINOX) and 
chemoradiation prior to re-evaluation for radical surgery seems to be the most appropriate way to 
manage borderline resectable lesions at the moment61,67.   
 
1.7.4. Management of  locally advanced pancreatic cancer 
When patients are not eligible for upfront resection but do not have overt metastatic disease, a 
multidisciplinary team should evaluate whether the tumour can be considered as BRPC or as truly 
unresectable, thus falling under the category of  locally advanced pancreatic cancer (LAPC). The 
average OS for patients with LAPC at presentation has been reported to be less than 1 year in a 
number of  studies. However, patients treated with chemotherapy alone in the more recent LAP07 
trial, which only recruited patients with LAPC, had a median OS of  16 months89. This difference 
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may be due to more active regimens used to treat tumours which progress to develop distant 
metastases.  
There is still a high degree of  controversy on how these patients should be managed. According 
to current ESMO guidelines, 6 cycles of  gemcitabine are still to be considered the standard of  care 
for patients with LAPC. The first cancer-directed treatment should be systemic chemotherapy; 
patients with disease control after 3–6 months of  chemotherapy could be treated with consolidative 
chemoradiotherapy67. 
These recommendations come as the result of  decades of  trials comparing upfront CRT with 
chemotherapy alone and induction chemotherapy (ICT) followed by CRT.  
In one of  the most recent studies, the FFCD/SFRO trial, patients were randomised to receive 
either gemcitabine monotherapy or a nowadays outdated CRT regimen (60 Gy plus infusional 5-
FU and cisplatin) followed by maintenance gemcitabine. The outcomes concerning terms of  
overall survival (8.6 months vs. 13 months, p = 0.03) and severe toxicities were worse in the CRT 
arm, possibly because of  the unfavourable safety profile associated with such a high dose of  
radiation, exceeding the tolerance of  the peri-pancreatic organs90.  
The ECOG E4201 randomised phase III trial was aimed to compare gemcitabine alone with 
gemcitabine-based CRT followed by maintenance gemcitabine, but it had to close due to low 
accrual rate after the inclusion of  74 patients91. In contradiction with the results of  the  FFCD-
SFRO trial, the analysis of  the patients included in the ECOG E4201 trial showed that median OS 
was better in the CRT arm (11.1 months vs. 9.2 months, p = 0.04). However, again, grade 4 
toxicities were more frequent in the CRT arm. The ECOG E4201 trial would point out a superiority 
of  gemcitabine to 5-FU as a radiosensitizer in LAPC, while a randomised phase II study indicated 
that capecitabine could be less toxic and more active than gemcitabine in this setting92. 
The reason why ICT is recommended to be given before chemoradiation is that the low doses 
of  chemotherapeutic agents used as radiosensitisers in CRT fail to control microscopic systemic 
disease efficiently, so approximately one-third of  patients with LAPC develop distant metastases 
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within 3 months. Patients who do not progress after 3-4 months of  systemic chemotherapy may 
then potentially benefit from CRT, as shown by two large retrospective studies93,94. The 
international phase III trial LAP07 compared gemcitabine with gemcitabine plus erlotinib as 
induction and maintenance chemotherapy (no significant difference in OS) and was also intended 
to look into the role of  CRT in patients with no progression after ICT, as opposed to the 
continuation of  chemotherapy for two more cycles. The results indicated that the OS of  patients 
treated with CRT after 4 months of  induction chemotherapy is not significantly different from that 
of  patients who go on receiving systemic chemotherapy, even though there was a trend towards 
longer PFS in the CRT arm (median PFS 9.9 months vs. 8.4 months, p=0.06) and locoregional 
tumour progression was less common in the CRT group (32% vs. 46%, p = 0.035)89. In conclusion, 
these data highlight that standard CRT improves local control (LC) but not OS. However, LC is 
essential for patients with LAPC: up to 30% of  patients with LAPC could die as a result of  local 
progression. New radiation techniques, such as stereotactic body radiation therapy (SBRT), could 
prove instrumental in overcoming the limitations of  CRT95. SBRT has been shown to offer 
excellent LC (1-year LC rate of  78%) with minimum acute and late grade ≥2 gastrointestinal 
toxicity rate in a recent multicenter phase II study96, as a result of  effective delivery to the tumour 
tissue and better sparing of  the peri-pancreatic organs such as the duodenum. SBRT enables the 
delivery of  ablative radiation doses (in the above-mentioned study, 33 Gy) in ≤5 sessions; patients 
with disease control after induction chemotherapy could receive SBRT and then quickly go back 
to fully-intensive systemic chemotherapy, avoiding the delay associated with conventionally 
fractioned CRT95. This treatment strategy is the object of  a phase III trial underway at the present 
time (NCT01926197)97.  
Newer regimens such as FOLFIRINOX and gemcitabine plus nab-paclitaxel have not been 
examined in randomised controlled trials in the setting of  LAPC yet. However, given that they 
already have been used quite extensively, and the studies in patients with metastatic PDAC have 
clearly demonstrated their efficacy and safety in that setting, according to the latest ASCO 
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guidelines, they may be recommended for people with LAPC with good performance status 
(ECOG PS 0 or 1), while gemcitabine only or gemcitabine plus capecitabine are a better option in 
patients with a borderline performance status98. In particular, the findings of  a number of  small 
retrospective and prospective studies suggest that FOLFIRINOX could obtain an impressive 
response rate in patients with LAPC, and may make a small but significant proportion of  patients 
with LAPC resectable. In two meta-analyses regarding the use of  FOLFIRINOX as induction 
chemotherapy in LAPC, just above one-quarter of  patients underwent surgery after 
FOLFIRINOX (pooled resection rates: 26.1% and 25.9% respectively)88,99. In the latest, Suker and 
co-workers reported a median OS of  24.2 months for patients who received FOLFIRINOX99, 
while several studies indicated a range of  6–13 months for patients with LAPC treated with 
gemcitabine. However, none of  the studies considered was a randomised trial, so higher-level 
evidence is required. Findings from the ongoing phase III PRODIGE 29/NEOPAN trial 
(NCT02539537)100, which compares FOLFIRINOX with gemcitabine in LAPC, may provide a 
definite insight into the efficacy of  this regimen in locally advanced pancreatic cancer. 
 
1.7.5. Treatment of  metastatic pancreatic cancer 
Chemotherapy is the mainstay of  the treatment of  metastatic pancreatic ductal adenocarcinoma 
(mPDAC). A pivotal study by Burris and co-workers78 established gemcitabine as the standard of  
care for patients with mPDAC in 1997. 126 patients were randomised to receive either gemcitabine 
or bolus 5-FU. The primary endpoint of  the study was clinical benefit response, resulting from the 
combination of  measurements of  pain (intensity, analgesic consumption), Karnofsky performance 
status, and weight. A significant difference was found as regards this parameter, with clinical benefit 
response achieved in 23.8% of  patients treated with gemcitabine and only 4.8% of  patients treated 
with 5-FU, thus demonstrating that gemcitabine is more effective than 5-FU in alleviating disease-
related symptoms in mPDAC. An additional finding was an objective response rate of  5.4% for 
the gemcitabine arm, compared to 0% of  the 5-FU arm; median survival was slightly but 
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significantly higher in the patients who received gemcitabine, at 5.65 months, as opposed to 4.41 
months for the ones treated with 5-FU, the 1-year survival rates being 18% and 2% respectively. 
These results highlight a modest survival advantage with gemcitabine. 
Gemcitabine is a nucleoside analogue similar to cytidine; it is usually administered weekly at a 
dose of  1000 mg/ m2 for 3 every 4 weeks. Treatment is generally well tolerated; adverse reactions 
include dose-limiting myelosuppression (neutropenia, thrombocytopenia, although in some 
patients thrombocytosis can also occur), flu-like symptoms (fever, muscle pain, chills, and fatigue), 
mild nausea, vomiting, peripheral oedema, and skin rash101. 
The past few years have witnessed a breakthrough in the treatment of  advanced pancreatic 
cancer. Two new chemotherapy regimens have been proven to be significantly more active than 
gemcitabine alone in large, well-executed, randomised phase III trials: FOLFIRINOX and 
gemcitabine plus nab-paclitaxel102,103.  
FOLFIRINOX, as mentioned above, is a combination of  three chemotherapeutic agents, 5-FU, 
irinotecan, and oxaliplatin, plus folinic acid (also called leucovorin, LV), a derivative of  
tetrahydrofolic acid which enhances the action of  5-FU. Oxaliplatin is administered first (85 
mg/m2) as a 2-hour intravenous infusion, with the addition, after 30 minutes, of  irinotecan at a 
dose of  180 mg/m2, given as a 90-minute infusion, followed by an intravenous bolus of  5-FU (400 
mg/m2) and then continuous intravenous infusion of  2400 mg/m2 of  5-FU over a 46-hour period 
thanks to the use of  an elastomeric infusion pump and a central line. Overall, the administration 
of  this chemotherapy regimens lasts 48 hours and is repeated every 2 weeks.  
In the  PRODIGE4/ACCORD11 study, a multicenter phase II/III trial carried out in France, 
whose outcomes were the subject of  a paper published in 2011 by Conroy and colleagues102, 342 
patients with histologically confirmed mPDAC not previously treated with chemotherapy were 
randomised to receive either FOLFIRINOX or gemcitabine. Patients had to be fit for aggressive 
chemotherapy so as to receive FOLFIRINOX. As a results, in order to be eligible for inclusion, 
they had to be 75 years old or younger, have adequate bone marrow, liver and kidney function, have 
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bilirubin levels <1.5 times the upper limit of  the normal range (<1.5 x ULN), and have an Eastern 
Cooperative Oncology Group performance status (ECOG PS) of  0 or 1. An ECOG PS 0 indicates 
that the patient is either fully active and able to carry on all pre-disease activities without restriction, 
while a patient with ECOG PS 1 is restricted in physically strenuous activity but is ambulatory and 
able to carry out work of  light or sedentary nature104. Notably, in the population considered, more 
patients had a tumour located in the body or tail of  the pancreas (59%) than in the head (38%), 
probably because bilirubin levels had to be normal or subnormal for inclusion.  
FOLFIRINOX was found to be superior to gemcitabine in all outcome measures. The median 
OS was 11.1 months in the FOLFIRINOX group, as opposed to 6.8 months for the gemcitabine 
group (hazard ratio for death, 0.57; 95% CI, 0.45 to 0.73; p<0.001); median PFS was reported to 
be 6.4 months in the in the FOLFIRINOX group, compared to 3.3 months for the gemcitabine 
group (hazard ratio for disease progression, 0.47; 95% CI, 0.37 to 0.59; p<0.001) (Fig. 9). Response 
rates according to RECIST criteria were 31.6% and 9.4% for patients treated with FOLFIRINOX 
and gemcitabine respectively (p<0.001)102.  
The toxicity profile of  FOLFIRINOX, a triplet chemotherapy, was less favourable than that of  
gemcitabine monotherapy, with higher rates of  severe (grade 3 or 4) toxicities such as neutropenia 
(45.7% vs. 21.0%), febrile neutropenia (5.4% vs. 1.2%), thrombocytopenia (9.1% vs. 3.6%), 
diarrhoea (12.7% vs. 1.8%), and sensory neuropathy (9.0% vs. 0%), whereas the only grade 3-4 
toxicity occurring more frequently in the gemcitabine arm was alanine aminotransferase elevation 
(7.3% vs. 20.8%)102.  
Nonetheless, the matter concerning increased toxicities with FOLFIRINOX and quality of  life 
was dealt with in a subsequent paper by the same group105, by means of  further investigation of  
the patients included in the PRODIGE4/ACCORD11 trial. Achieving the best possible health-
related quality of  life should be one of  the most significant purposes of  treatment for patients with 
mPDAC because of  the short life expectancy and the fact that patients are usually highly 
symptomatic when diagnosed. In this work, the investigators employed the European Organisation 
  
33 
for the Research and Treatment of  Cancer Quality of  Life Questionnaire C30 (EORTC QLQ-30) 
to assess the global health status, the level of  functioning in various domains, and the severity of  
symptoms in 342 patients randomised to be treated with gemcitabine or FOLFIRINOX. The 
findings clearly showed that, despite the increased toxicities associated with FOLFIRINOX, there 
were no notable differences between the two arms concerning quality of  life in the domains 
examined in the EORTC QLQ-C30, except for diarrhoea, which seemed to affect patients in the 
FOLFIRINOX group predominantly in the first two months of  treatment. Notably, time until 
definitive deterioration  (the time span after which QLQ-C30 score decreased by more than 20 
points compared to the baseline score) was significantly higher for the FOLFIRINOX arm as for 
global health status, physical, role, cognitive, and social functioning, and six symptom domains 
(fatigue, nausea/vomiting, pain, dyspnea, anorexia, and constipation). These findings demonstrated 
that a clinically meaningful prolongation of  quality of  life can be achieved adopting FOLFIRINOX 
as opposed to gemcitabine in patients fit for polychemotherapy, in spite of  the less favourable 
safety profile of  this regimen105. 
After more than a decade of  unsuccessful randomised trials aiming to add another cytotoxic 
agent to gemcitabine, the MPACT trial, whose results were published in 2013, demonstrated the 
efficacy of  gemcitabine plus nab-paclitaxel in this setting103. 
Nab-paclitaxel (nanoparticle albumin-bound paclitaxel) is a solvent-free colloidal suspension of  
the taxane and human serum albumin. This agent targets one of  the main factors which causes 
pancreatic cancer to be resistant to chemotherapy: the fact that cytotoxic drugs fail to reach high 
concentrations within the tumour tissue. This is due to the desmoplastic reaction of  the stroma, 
which causes a rise in interstitial fluid pressure, which, in turn, impairs transport of  molecules from 
the vessels to the tumour tissue, diminishing the delivery of  chemotherapeutic agents to malignant 
cells106. The secreted protein acidic and rich in cysteine (SPARC), a multifunctional glycoprotein 
overexpressed in pancreatic adenocarcinoma, modulates the malignant cells-ECM interaction, plays 
a pivotal role in tumour growth and migration, promotes angiogenesis, and is probably involved in 
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tumour escape by inhibiting immune surveillance. SPARC binds albumin and has been 
hypothesised to mediate the transport of  albumin from the ECM to tumour cells. Nab-paclitaxel 
takes advantage of  albumin as a carrier for hydrophobic molecules in the blood and exploits its 
transcytosis across vascular endothelium; albumin’s binding to SPARC allows then the intratumoral 
accumulation of  this drug106. Moreover, nab-paclitaxel has been found to increase the 
concentration of  gemcitabine in tumour cells by reducing the levels of  cytidine deaminase, the 
primary enzyme involved in gemcitabine metabolism, through reactive oxygen species-mediated 
degradation107.   
The MPACT trial was an international, multicenter, phase III study in which 861 patients with 
mPDAC were randomised to receive either gemcitabine alone or gemcitabine plus nab-paclitaxel103. 
In both arms, chemotherapy was administered weekly for 7 out of  8 weeks (first cycle), whereas in 
the subsequent cycles gemcitabine or gemcitabine plus nab-paclitaxel were given weekly for 3 every 
4 weeks. Nab-paclitaxel was administered in a 30-to-40-minute intravenous infusion at a dose of  
125 mg/m2, followed by a 30-minute infusion of  1000 mg/m2 of  gemcitabine. 
Eligible patients had histologically confirmed mPDAC, had not previously received 
chemotherapy for advanced disease and were required to have adequate hematologic, hepatic, and 
renal function and a Karnofsky performance status of  70% or more. 
The primary endpoint of  the study by von Hoff  and colleagues was overall survival, while 
progression-free survival and response rate (RR) were secondary endpoints. The median OS was 
significantly longer in the gemcitabine plus nab-paclitaxel group, at 8.5 months, as opposed to 6.7 
months with gemcitabine only (hazard ratio for death, 0.72; 95% CI, 0.62 to 0.83; p<0.001). 
Similarly, patients treated with gemcitabine plus nab-paclitaxel had a significantly longer PFS, with 
a median of  5.5 months, compared to 3.7 months for patients treated with gemcitabine alone 
(hazard ratio for disease progression or death, 0.69; 95% CI, 0.58 to 0.82; p<0.001) (Fig.10). The 
RR of  the new regimen was more than triple that of  gemcitabine: 23% vs. 7% (p<0.001)103. 
Gemcitabine plus nab-paclitaxel has a relatively favourable safety profile, with an only slightly 
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higher proportion of  patients facing severe (grade 3 or 4) toxicities (50% vs. 43%) compared to 
gemcitabine monotherapy. Grade 3 or higher adverse effects reported more often in the 
gemcitabine plus nab-paclitaxel group included neutropenia (38% vs. 27%), fatigue (17% vs. 7%), 
and peripheral neuropathy (17% vs. 1%)103.  
No randomised clinical trial directly compared gemcitabine plus nab-paclitaxel and 
FOLFIRINOX. Cross-trial comparison is not entirely reliable: the selection criteria for patients in 
the two above-mentioned studies were somewhat different, e.g. patients aged over 75 were excluded 
from the PRODIGE4/ACCORD11 study, while more than 10% of  the patients included in the 
MPACT trial were aged 75 years or older, the eldest being 88 years old.  Nonetheless, available data 
would suggest that FOLFIRINOX is more active, but also more toxic87. 
Current guidelines, in the absence of  a head-to-head comparison, recommend both 
FOLFIRINOX and gemcitabine plus nab-paclitaxel for the treatment of  patients with mPDAC 
whose ECOG PS is 0 or 1, whose bilirubin level are below 1.5 x ULN and who have a favourable 
comorbidity profile (i.e. normal or subnormal blood work values, liver and kidney function, and 
absence of  comorbid medical conditions requiring active ongoing medical care, such as congestive 
heart failure, chronic obstructive pulmonary disease, uncontrolled diabetes mellitus, and 
neurological disorders)67,108. It is worth noting that ASCO recommends FOLFIRINOX for patients 
with a “favourable” comorbidity profile, while gemcitabine plus nab-paclitaxel is recommended for 
patients who have a “relatively favourable” comorbidity profile108, suggesting the adoption of  this 
less toxic, but probably less effective regimen, for the first-line treatment of  patients who are fit 
for polychemotherapy, but whose global health status is slightly worse than that of  patients eligible 
for FOLFIRINOX.  
No more than half  patients presenting with metastatic disease at diagnosis are suitable for 
aggressive chemotherapy. For patients with ECOG PS 2 and/or bilirubin levels > 1.5 x ULN, 
monotherapy with gemcitabine is appropriate, while patients with significant uncontrolled 
comorbidities, a very poor performance status (ECOG PS 3 or 4), or a presumably very short life 
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expectancy are not eligible for cancer-directed therapy and should be treated with best supportive 
care only67,108.  
A number of  targeted therapy agents have been tested in mPDAC, but the results of  all phase 
III trials have been negative. The only exception was the combination of  gemcitabine and the 
EGFR tyrosine kinase inhibitor erlotinib, which obtained a 12-day improvement in median OS109. 
Albeit statistically significant, this is highly likely to be clinically irrelevant and to be achieved at the 
cost of  increased toxicity. As a consequence, despite the approval of  this doublet, this regimen has 
not been widely used in the routine clinical activity.   
A subgroup of  patients with good performance status after the failure of  first-line treatment 
could benefit from second-line chemotherapy. No randomised clinical trial to date has investigated 
second-line therapy after FOLFIRINOX or gemcitabine plus nab-paclitaxel. According to the most 
up-to-date ASCO guidelines, gemcitabine plus nab-paclitaxel could be offered as second-line 
treatment after FOLFIRINOX, while 5-FU/LV plus oxaliplatin (FOLFOX), irinotecan 
(FOLFIRI), or nanoliposomal irinotecan could be used after first-line therapy with gemcitabine 
plus nab-paclitaxel108. The only randomised trials whose results are available concern mPDAC 
progressed on first-line gemcitabine. The CONKO-003 phase III trial compared a 5-FU/LV plus 
oxaliplatin (OFF regimen), with 5-FU/LV alone for gemcitabine-refractory mPDAC, showing a 
longer OS for patients treated with the combination regimen (5.9 months vs. 3.3 months)110. 
However, the analogue and more recent PANCREOX trial failed to confirm these results111. Last 
year, the outcomes of  the NAPOLI-1 phase III trial were published: 5-FU/LV plus nanoliposomal 
irinotecan was reported to achieve better OS (6.1 months vs. 4.2 months), PFS (3.1 months vs. 1.5 
months), and RR (16% vs. 1%) than 5-FU/LV alone112. According to the current ESMO guidelines, 
considering the inconsistent results regarding the use of  oxaliplatin, 5-FU/LV plus nanoliposomal 
irinotecan may become the best option for second-line chemotherapy in patients previously treated 
with gemcitabine67. 
All in all, despite the significant advances of  the last years, the prognosis of  patients who present 
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with metastatic disease and are treated with the newest chemotherapy regimens is still grim, with a 
median survival inferior to 12 months.  
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Chapter 2. Circulating tumour DNA: the “liquid biopsy”. 
 
2.1. Accessing tumour DNA via tissue sampling: biopsy and related issues 
Alterations in the genome of  malignant cells are highly informative in clinical oncology. Specific 
mutations, for instance, can act as prognostic or predictive markers. For example, positivity for Her-
2/neu amplification in breast cancer is a marker of  worse prognosis and predicts response to anti-
Her-2 antibodies such as trastuzumab or pertuzumab113, while KRAS, NRAS and BRAF mutations 
in colorectal cancer predict resistance to therapy with the anti-EGFR monoclonal antibodies 
cetuximab and panitumumab114–116. 
Targeted therapies usually rely on the acquisition of  tumour tissue for molecular analysis before 
initiation of  treatment. Tissue sampling by biopsy or surgical excision is the gold standard both for 
histological examination with the purpose of  making a conclusive diagnosis and for the molecular 
analysis of  specific cancer-associated genomic aberrations. Apart from the ones mentioned above, 
clinical applications include detection of  EGFR mutations for treatment with EGFR tyrosine 
kinase inhibitors (TKIs) such as erlotinib and gefitinib117 and ALK mutations for therapy with 
crizotinib in non-small cell lung cancer118, BRAF mutations for BRAF inhibitors (e.g. vemurafenib, 
dabrafenib) in melanoma119,120, and c-KIT mutation to initiate imatinib in gastrointestinal stromal 
tumours121. In pancreatic cancer, however, targeted therapy has proven of  little use, the only 
targeted agent approved being erlotinib in association with gemcitabine109, a far less active treatment 
than FOLFIRINOX or gemcitabine plus nab-paclitaxel.  
Tissue sampling via biopsy is a technique that poses major issues: biopsies are an inconvenience 
from a scheduling perspective, possibly delaying the initiation of  treatment, are highly expensive, 
and are invasive, painful manoeuvres whose results may not influence the outcome. Last, but not 
least, biopsies are not without risks. A work conducted at MD Anderson Cancer Center reported 
adverse event rates of  17.1% and 1.6% respectively for thoracic and abdominal/pelvic sampling122. 
Concerns have also been raised regarding very rare, but possible tumour seeding along the needle 
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tract123: for example, transscrotal biopsy in testicular cancer is not recommended124, because 
malignant cells could be left in the scrotum and spread to inguinal lymph nodes.  
The number of  malignant cells in each biopsy varies and is largely dependent on the tumour 
cellularity and size of  the specimen acquired; fine-needle aspirates, for instance, only allow the 
collection of  a very limited amount of  tumour tissue in comparison with surgically resected 
specimens.  
Another important matter is sample preservation. Most tumour biopsies are preserved in the 
form of  formalin-fixed paraffin-embedded (FFPE) blocks; during fixation with formalin, a number 
of  chemical reactions occur, including DNA denaturation, fragmentation and introduction of  
nonreproducible sequence alterations. The majority of  point mutations in the genome of  cells 
contained in an FFPE block are C:G > T:A changes as a consequence of  cytosine deamination to 
uracil125. As a result, formalin fixation does not allow adequate preservation of  high-molecular-
weight DNA, with up to 30% of  nucleic acids possibly lost during fixation. A review of  mutation 
detection failures indicated an 11.9% rate of  missed mutations; 80% of  these are attributable to 
pre-PCR error126.  
Another major limitation of  tissue biopsy is tumoral heterogeneity, a feature of  most advanced 
cancers127. Malignancies are dynamic, with different genetic profiles (type and proportion of  
specific genetic alterations) to be found in various areas of  the same tumour - i.e., intratumoral 
heterogeneity; the same is applicable for different metastases within the same patient - i.e., 
intermetastatic heterogeneity128. A biopsy can only sample tissue from a zone of  one selected 
lesion, thus missing the intratumoral and intermetastatic heterogeneity. Moreover, a biopsy is a 
single snapshot of  the evolution of  the sampled area of  the tumour in time129: our knowledge of  
the genetic composition of  the tumour as a whole is therefore drastically limited, and, as a result, 
the factors causing primary or secondary resistance often remain unknown.  
Due to genomic instability, tumours are in constant evolution, and new clones arise during 
progression. Medical therapy adds a selection pressure: resistant subclones emerge as a result of  
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additional aberrations in the pathways related to the mechanism of  action of  the agent used. In 
malignancies in which patients diagnosed even in advanced stages enjoy a relatively long survival, 
such as breast or prostate cancers, the molecular analysis of  biopsies conducted many months (or 
even years) before, during which a number of  lines of  treatment have been administered, may very 
possibly be inadequate to understand the biology of  the tumour at the time of  initiating a new 
therapy130. Although rebiopsying a selected lesion at any therapeutic decision point could seem a 
solution to this issue, because of  the invasiveness and morbidity associated with the procedure, 
molecular analysis is usually performed on archival tumour tissue129,130.  
In conclusion, a biopsy can be a difficult, painful and potentially harmful procedure, is a single 
photograph of  the tumour in time, and is subject to selection bias as a result of  intratumoral and 
intermetastatic heterogeneity. It is thereby clear that new procedures through which to analyse the 
genetics of  cancer are urgently needed. These new techniques should have the following features: 
be rapid, cost-effective, be less invasive than a biopsy, provide a picture of  all the genetic patterns 
present in a malignancy, and allow the clinician to keep up with the genomic alterations that occur 
in cancer cells exposed to therapy.  
 
2.2. The liquid biopsy 
The “liquid biopsy”, i.e. the extraction, quantification, and characterisation of  circulating 
tumour cells or circulating tumour DNA (ctDNA) from a sample of  peripheral blood, is a very 
intriguing procedure in the respect mentioned above.  
During the history of  an invasive carcinoma, malignant cells overstep the basal membrane and 
invade the underlying connective tissue, where they can intravasate in blood and lymphatic vessels. 
Tumour cells free in the peripheral blood, possibly on their way to colonise distant organs forming 
metastases, are known as circulating tumour cells (CTCs) and have been the subject of  extensive 
investigation during the past few decades. CTCs have been proven to be a prognostic marker in a 
number of  tumours, including breast, colorectal, prostate and lung cancer131–133. 
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The analysis of  cell-free circulating tumour DNA is another possible technique that may 
supplement or replace tissue biopsies. DNA can be isolated from the cell-free portion of  peripheral 
blood as low-molecular-weight fragments (<1000 bp). As the procedure is only minimally invasive 
(venipuncture) for the patient and the testing is relatively inexpensive, the liquid biopsy can be 
repeated many times. This would enable longitudinal monitoring of  the patient and the acquisition 
of  actionable, real-time information on the current genetic profile of  the tumour whenever a new 
therapy must be initiated134–136.  
 
2.3. Circulating tumour DNA: biological aspects 
The presence of  cell-free nucleic acids in the blood was reported for the first time by Mandel 
and Metais137 in 1948 but went overlooked for at least a couple decades, when Tan et al. found that 
both free DNA and anti-DNA antibodies could be detected in the serum of  patients with systemic 
lupus erythematosus138.  
Circulating cell-free DNA (cfDNA) has been the subject of  extensive research in a number of  
clinical fields, such as stroke, myocardial infarction, end-stage kidney failure, transplants, surgery, 
trauma, and pregnancy, showing that cfDNA can be detected at a basal concentration in a steady-
state context, and its levels soar in case of  cellular injury or necrosis134. 
The first investigators to report findings suggesting the potential interest of  cfDNA in the 
oncologic setting were Leon and co-workers139 in 1977, who described elevated levels of  cfDNA 
in approximately half  the members of  a group of  173 patients undergoing radiotherapy for several 
different malignancies. Patients with metastatic disease were found to have greater amounts of  
DNA in their serum, compared to those with localised disease; DNA levels decreased remarkably 
after radiotherapy, with persistently high or rising cfDNA concentrations associated with a lack of  
response to treatment.  
Even more intriguingly, in 1989, Stroun et al.140 showed that circulating DNA in the plasma of  
oncologic patients shared biophysical properties (impaired strand stability) with DNA of  malignant 
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cells, thus suggesting the origin of  the increased levels of  cfDNA from cancer cells themselves, 
instead of  activated lymphocytes reacting towards the disease as an alternative theory would have 
implied.  
Moreover, circulating tumour DNA (ctDNA) can be discriminated from background cfDNA 
because the tumour genome, by definition, contains somatic genetic alterations. Several cancer-
specific mutations in oncogenes and tumour suppressor genes have been detected in circulating 
DNA: the first were NRAS in patients with myelodysplastic syndrome and acute myelogenous 
leukaemia (AML)141, rearranged Ig heavy chains in patients with a B-cell malignancy such as non-
Hodgkin's lymphoma or acute B-precursor lymphoblastic leukaemia142, and KRAS mutations in 
colorectal143 and pancreatic cancer144. 
The mechanism through which tumour cells shed fragmented DNA into circulation has still to 
be ultimately determined. It has been suggested that all vital cells actively secrete DNA into the 
bloodstream145. In a study published in 2001, instead, Jahr et al.146 hypothesised that ctDNA 
originates from apoptotic and necrotic cells. The predominant form of  circulating DNA is a 
structure known as mononucleosome, in which a fragment of  DNA of  180-200 bp is associated 
with proteins; this is the result of  internucleosomal cleavage of  chromatin, a major feature of  
apoptosis, thus suggesting this process plays a pivotal role134,147. Circulating tumour DNA (ctDNA) 
is believed to be released from neoplasms primarily as a result of  necrotisation, while non-tumour 
cfDNA would originate from normal cells which undergo apoptotis148. In fact, what happens 
during the growth of  a neoplasm is that cellular turnover increases and more and more cells die 
from apoptosis and necrosis: while their remains are effectively cleared by macrophages under 
physiologic circumstances, within the mass cellular debris accumulates and is later released into the 
bloodstream (Fig. 11)134. For healthy subjects, the average concentration of  cfDNA was found to 
be around 10-30 ng/ml, while values for oncologic patients often exceed 100 ng/ml136.  
Malignancies composed of  about 50 million cancer cells release enough DNA for the detection 
of  ctDNA in blood; in contrast, usually, imaging can recognise masses of  approximately 7–10 mm 
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in size, containing roughly 1 billion cells135. 
The contribution of  cancer cells to total cfDNA is highly variable: the studies investigating this 
aspect have highlighted proportions ranging from 0.01% to 90% and more146,149. The passive release 
of  ctDNA from apoptotic or necrotic cells within the tumour depends on the site, size, and 
vascularity of  the mass, possibly explaining the high degree of  variation in ctDNA concentrations 
and mutant fractions134. 
 As ctDNA often represent less than 1% of  total cfDNA, with an absolute concentration 
ranging from 1 to 100 ng/ml, its measurement can be challenging. Early studies would use both 
serum and plasma to extract ctDNA: as during coagulation the lysis of  leukocytes can occur, 
increasing the quantity of  non-tumour circulating DNA, the plasma would seem to better reflect 
the in vivo levels of  circulating DNA147,150. Also, the plasma may contain a higher concentration of  
ctDNA, as EDTA indirectly inhibits blood DNases151. 
It has been demonstrated that the whole tumour genome can be reconstructed from its small 
circulating fragments; the fact that whatever DNA segment contained in the cells of  the tumour 
can potentially be found in ctDNA justifies the term “liquid biopsy”129. 
There are few data available concerning the stability of  ctDNA in the blood: clearance seems 
to be rapid, with a half-life of  less than 2 hours, and the spleen, liver, and kidneys could be the 
responsible organs129. 
The analysis of  ctDNA can be performed with two possible approaches. The first one targets 
known genetic alterations of  the tumour, such as mutations in EGFR and KRAS. The detection 
of  mutant alleles in very low proportions is nowadays possible thanks to highly sensitive 
technologies such as ARMS (amplification refractory mutation system), digital PCR (dPCR), and 
beads, emulsions, amplification, and magnetics (BEAMing)129. A number of  assays for driver 
mutations which hold implications for therapeutic decision-making exist. The other possible 
approach, instead, is untargeted and, therefore, does not require previous knowledge of  the genetic 
changes specific to the tumour. A genome-wide analysis of  the liquid biopsy is carried out thanks 
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to next-generation sequencing (NGS) techniques129, which, however, have a lower sensitivity than 
the above-mentioned methods (Figure 12)134.  
A liquid biopsy with ctDNA would have a number of  benefits, compared to tissue biopsy (Table 
5). First and foremost, it is a minimally invasive method to analyse tumour genome, thus avoiding 
the possible adverse events of  tumour tissue sampling and enabling repetition at multiple time 
points. Consecutive liquid biopsies would provide, in a way, a “video” of  the evolution of  the 
molecular profile of  the tumour, instead of  relying on the single photograph given by the 
conventional biopsy. Secondly, given the fact the ctDNA is released into the bloodstream from all 
the sites of  disease, both the primary tumour and distant metastases, intra-tumoral and inter-
metastatic heterogeneity are adequately taken into account by liquid biopsy, while tissue biopsy is 
suboptimal in this respect. Lastly, the blood is a source of  fresh DNA, not altered by fixatives. 
In a number of  studies it has been investigated if  the detection of  cancer-specific mutations 
would be consistent in tissue specimens and liquid biopsies: sensitivity and specificity have generally 
been satisfactory. A French study was the first to report multiplexed detection of  targetable 
mutations in a population of  patients with metastatic cancer (multiple histological types) included 
in a prospective trial152. Molecular analysis of  tissue biopsy and liquid biopsy had minimal 
discrepancy: 29 mutations were identified in the tissue samples, of  which 28 were found in the 
liquid biopsies as well (sensitivity: 97%), and one additional mutation in a liquid biopsy only. This 
latter finding is quite frequent and is usually interpreted as a consequence of  the fact that tumour 
heterogeneity is effectively dealt with by ctDNA analysis. 
 
2.4. Circulating tumour DNA as a new tumour marker 
Liquid biopsy with ctDNA could be adopted for a bunch of  different purposes in clinical 
activity. Possible applications include its adoption as a novel biomarker, similarly to protein tumour 
markers already employed in the clinical practice, to monitor response to treatment, precociously 
detect progression, identify minimal residual disease, evaluate molecular heterogeneity, or provide 
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an early diagnosis of  disease135. In other words, ctDNA has the potential to become a diagnostic, 
predictive, and prognostic marker in the management of  cancer (Table 6). 
 
2.4.1. Monitoring of  treatment response and tumour burden  
Disease burden is usually assessed with imaging; serum biomarkers such as PSA, CEA, CA-125, 
CA15-3 and CA19.9 can be helpful in evaluating response to treatment, particularly when it may 
be difficult to discriminate between the tumour and surrounding tissue reactions and imaging 
results could be inconclusive. However, many cancers lack a reliable circulating protein marker, and 
these often have suboptimal sensitivity and specificity, with a substantial proportion of  false 
negatives and false positives. For instance, as mentioned above, serum CA19.9 levels can increase 
because of  various non-malignant pancreatobiliary conditions in which the biliary excretion of  the 
antigen is impaired50. Furthermore, the half-life of  protein markers is usually in the order of  weeks; 
as a result, a similar time span between measurements is required, and months can be necessary to 
see a reliable trend134. 
A comparison of  protein tumour markers with ctDNA clearly shows some pros of  the latter. 
ctDNA has high specificity: somatic cancer mutations are, by definition, present in tumour DNA 
and absent in wild-type, normal DNA; this avoids the occurrence of  false positives as for imaging 
and protein markers. The short half-life of  ctDNA (according to Diehl et al.149, just under 2 hours) 
allows a much more frequent assessment of  tumour dynamics. As a result of  the shorter half-life, 
ctDNA has a notable depth of  response, too, with changes in ctDNA reported to anticipate 
variations in protein marker levels and radiological responses by weeks or even months149,153.     
In a way similar to viral load changes (e.g. HIV, HBV, HCV viral load), rises and falls in ctDNA 
correlate with the clinical course of  the disease. As regards patients with advanced tumours 
receiving medical therapy, works concerning several malignancies have investigated this potential 
application of  ctDNA to monitor treatment response: colorectal cancer (CRC)149, gastric cancer154, 
melanoma155–157, breast cancer153 and non-small cell lung cancer (NSCLC)158,159. Findings have 
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generally been consistent: progression of  disease is associated with rapid increases in ctDNA levels 
while successful medical therapy and surgery correspond to drops in ctDNA levels134.  
Intriguingly, Diehl and co-workers149 reported that no patient with undetectable ctDNA after 
surgery for colorectal cancer experienced recurrence of  disease, while this was the case for all but 
one of  the subjects with detectable ctDNA after resection surgery within a year. High 
concentrations of  plasma mutant KRAS were proven to be negative prognostic markers in patients 
with metastatic colorectal cancer160,161. 
A Japanese study focusing on disease recurrence after gastrectomy for gastric cancer indicated 
that circulating mutant TP53 levels, and not total cfDNA concentration, showed a good correlation 
with the disease status, decreasing remarkably after radical (R0) surgery and less so after R1 and R2 
resections, and increasing at recurrence.  
Shinozaki and colleagues155 found that in a group of  20 patients with advanced melanoma 
treated with polychemotherapy and immunotherapy, after treatment serum mutant BRAF was 
detectable in only 10% of  the patients who responded to biochemotherapy, while it was measurable 
in 70% of  non-responders. It was also pointed out that the detection of  serum mutant BRAF is 
associated with shorter overall survival. In a study by Lipson et al.156, twelve patients undergoing 
treatment with immune checkpoint blockade were tracked using specific ctDNA hotspot mutations 
in BRAF, cKIT, NRAS and other genes; ctDNA variations correlated with clinical and radiological 
outcomes. Sanmamed et al.157 instead reported that in a group of  20 patients with BRAF V600E 
mutation treated with vemurafenib or dabrafenib baseline plasma mutant BRAF correlated with 
tumour burden and was associated with poorer PFS and OS, and ctDNA levels increased at disease 
progression compared to best response. 
Dawson et al.153 successfully detected ctDNA in 29 out of  30 patients with breast cancer with 
pre-determined genetic alterations (point mutations in PIK3CA and TP53, structural variants) at 
molecular analysis of  archival tissue specimens. The authors indicated that ctDNA, compared to 
CTCs and CA15-3, had a greater dynamic range and better correlation with changes in tumour 
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load as seen on imaging. In 53% of  the patients with progressive disease, increasing levels of  
ctDNA were detected on average 5 months (range 2-9 months) before progression of  disease was 
confirmed radiologically; increasing levels of  ctDNA correlated with inferior overall survival. 
Given the dramatic effects of  EGFR-TKIs on EGFR-mutant NSCLC and the fact that there 
are not so highly prevalent mutations in oncogenes and tumour suppressor genes in NSCLC as, 
for instance, in pancreatic and colorectal cancer, research has been focusing mainly on mutant 
EGFR ctDNA. In a study by Imamura et al.159 about EGFR-mutated patients treated with EGFR-
TKIs, ctDNA responses during therapy correlated well with radiological changes in radiological 
good responders, while the association was marginal in non-responders. The investigators 
speculated that tumours which had a complete/partial radiological response would be mostly 
composed of  cells with activating EGFR mutations, while patients with stable disease or 
progression of  disease but positive ctDNA responses might have a tumour which is a mixture of  
wild-type EGFR and mutant EGFR cancer cells. This study also addressed a very significant issue 
as regards liquid biopsy, the time span after which subsequent samples should be collected after 
baseline assessment. The investigators reported that early (< 1 month) ctDNA levels were not 
good predictors of  radiological response to treatment, because ctDNA levels could soar early after 
the initiation of  medical therapy due to rapid tumour necrosis. Another interesting outcome was 
that in the 11 patients out of  17 with radiologically confirmed progression in which EGFR ctDNA 
levels increased during therapy, ctDNA changes anticipated radiological findings by an average of  
4 weeks. An elevated EGFR T790M ctDNA concentration was detectable in 52% of  patients 
experiencing progression of  disease: T790M is the main secondary mutation causing resistance to 
EGFR-TKIs, present in 50-60% tumours progressing after first-line biological therapy. New agents 
such as osimertinib and rociletinib are active in T790M EGFR-mutated NSCLC, and their efficacy 
has been shown in patients with a liquid biopsy positive for this mutation162. Another study had 
similar results, confirming that dynamic changes in EGFR ctDNA relative to baseline may predict 
response to treatment.158  
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In conclusion, data available in several malignancies suggest that ctDNA could be a useful 
biomarker to supplement imaging and protein markers to evaluate tumour load and treatment 
response. 
 
2.4.2. Monitoring of  tumour heterogeneity and resistance to targeted therapy 
ctDNA could also be used as a predictive marker for biological therapy. For instance, in CRC, 
mutant KRAS is a predictive marker for resistance to EGFR blockade, while in NSCLC mutations 
in EGFR predict response to therapy with EGFR TKIs. Patients often develop secondary 
resistance to these targeted agents within some months of  treatment. Liquid biopsy could be 
performed to examine the status of  the predictive genetic determinants instead of  tumour section 
analysis. The liquid biopsy would allow to bypass the issue of  repeated posttreatment tumour tissue 
sampling, as well as providing a better overall picture of  the genetic status of  the malignancy at 
multiple time points (Fig. 13).  
Several works have investigated the feasibility of  this approach in CRC. A study reported 92% 
sensitivity and 98% specificity for seven tested 7 KRAS mutations in ctDNA, with a concordance 
rate 96% compared to tumour specimen examination163. Other works indicated that 38% of  
patients treated with panitumumab developed detectable KRAS mutations in circulating DNA 
within 5-6 months of  treatment164, and the presence of  mutant oncogenes in circulation preceded 
radiological progression by an average of  10 months165.  
In NSCLC, instead, several works reported sensitivity and specificity of  liquid biopsy for EGFR 
mutations compared to tissue analysis of  65-75% and 93-100% respectively158,166–168. Overall, 
available data indicate that EGFR mutation detection in ctDNA could be used as a useful surrogate 
of  tissue-based testing to predict the clinical outcomes of  EGFR TKIs therapy, especially if  
tumour tissue is not available or the sample is exhausted158,167,168.  
The real-time assessment of  genetic markers predictive of  sensitivity or resistance to targeted 
therapy in the future will enable the clinician to switch towards alternative treatments or 
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combinational regimens suppressing the expansion of  clones potentially accountable for the failure 
of  treatment134,135. 
 
2.4.3. Monitoring of  minimal residual disease 
Another potential field in which ctDNA could prove useful is the adjuvant setting, after curative-
intent surgery. For example, in localised CRC or breast cancer, resection surgery alone cures a large 
proportion of  patients. However, at the moment we cannot determine which patients have been 
cured and which have a subclinical residual disease that will result in disease recurrence. As a 
consequence, patients with high-risk clinical and pathologic (TNM staging) criteria indiscriminately 
undergo adjuvant chemotherapy; however, a substantial fraction of  these subjects do not need such 
potentially toxic therapy. ctDNA could serve as a marker of  minimal residual disease after surgery, 
identifying the patients who have a high risk of  recurrence (Fig. 14). High sensitivity will be needed 
to detect the low levels of  ctDNA released from micrometastases not detectable by imaging. Tissue 
damage during surgery causes ctDNA levels to rise; as a result, ctDNA should be assessed 6-8 
weeks after surgery, before the initiation of  adjuvant therapy134,135. 
 Diehl et al.149 examined a cohort of  patients with CRC who underwent curative-intent resection. 
Eighteen patients were followed up for 2 to 5 years. This study showed that ctDNA could be 
sensitive enough to detect minimal residual disease after surgery. Virtually all patients with 
detectable postoperative ctDNA experienced recurrence of  disease; in contrast, all patients with 
undetectable ctDNA after surgery did not relapse.  
Tie et al.169 have presented at the 2016 ASCO Annual Meeting a prospective trial in 231 patients 
with stage II CRC, who had undergone surgery and were followed up with a liquid biopsy every 3 
months, starting 4-10 weeks after resection. 79% of  patients with positive ctDNA who received 
no adjuvant treatment experienced recurrent disease, while only 10% of  patient with undetectable 
ctDNA who did not receive adjuvant chemotherapy relapsed. Among subjects who received 
adjuvant treatment, ctDNA was detected in 6 patients early after resection; in all of  them, the 
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ctDNA status turned from positive to negative during chemotherapy but became positive again 
after completion of  adjuvant treatment in 2 patients, who both went on to develop a relapse. 
Considering all patients with several liquid biopsies available, ctDNA detection anticipated 
radiological recurrence by an average of  167 days. The authors proposed that ctDNA could reshape 
the design of  clinical trials in the adjuvant setting, as ctDNA analysis allows the clinician to identify 
a priori patients with minimal residual disease, who, therefore, are at high risk of  relapse, and also 
serves as a marker of  response to adjuvant chemotherapy. 
ctDNA has also been used in a study focusing on 20 patients with breast cancer to assess 
recurrence after neoadjuvant therapy and resective surgery170. The primary tumour was analysed 
using NGS and mutations were identified in 60% of  the tumours; tailored digital PCR assays were 
then used to evaluate ctDNA during follow-up. ctDNA was detected in 75% of  samples before 
neoadjuvant therapy, with no difference to be found between patients with and without recurrence 
of  disease. Four out of  the five patients with recurrent disease had specific ctDNA detectable in 
the first six months post-surgery; all the patients with detectable ctDNA relapsed and no patients 
who did not experience recurrence of  disease had detectable ctDNA post-surgery. The negativity 
of  ctDNA after surgery thus indicated total clearance of  the tumour. Remarkably, a patient with 
brain recurrence did not have detectable ctDNA at relapse.  
Taken together, these studies would suggest that ctDNA could be highly valuable in the 
management of  patients who underwent curative-intent surgery, revealing those patients who have 
residual disease and providing evidence of  the efficacy of  adjuvant treatment.  
 
2.4.4. Circulating tumour DNA for early diagnosis of  cancer 
As regards the potential employment of  circulating DNA as a diagnostic tool, the first 
approaches concerned the concentration of  total cfDNA in cancer patients as opposed to healthy 
control subjects. Although several works showed that oncologic patients have significantly higher 
levels of  cfDNA, thus enabling the confirmation of  cancer diagnosis or, vice versa, the 
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identification of  disease-free patients after curative-intent treatment171,172, others pointed out that 
the discriminatory power of  such a test would be very low173,174. Therefore, cfDNA alone without 
determination of  cancer-specific mutations is of  little use in this respect.  
Instead, the development of  assays for aberrations which are recurrent in cancers would seem 
promising for early detection of  cancer, because of  the exquisite specificity of  ctDNA and the day-
by-day increasing sensitivity of  the techniques involved. The available evidence suggests that 
benign tumours and nonneoplastic conditions do not release ctDNA in the bloodstream175, so false 
positives are unlikely. A positive result of  a screening test with ctDNA should raise concern, 
because of  the known causal relationships between the examined mutations and cancer. Nowadays, 
inclusion criteria for clinical trials usually include the histological/cytological demonstration of  the 
presence of  the tumour; in the future, clinical trials could allow the inclusion of  patients who have 
somatic mutations in circulating DNA. 
Bettegowda and co-investigators176 examined 410 patients with various cancers, reporting more 
than 80% of  patients with metastatic disease to have detectable levels of  ctDNA, a higher 
proportion than that of  most conventional markers177. A notable exception were malignancies 
arising in the central nervous system, which did not release detectable quantities ctDNA in the 
bloodstream as frequently: for example, only 10% of  patients with glioma were positive for 
ctDNA176.  
The same study took into consideration patients with localised disease, showing detectable 
ctDNA in 73, 57, 48 and 50% of  patients with CRC, gastroesophageal cancer, pancreatic cancer 
and breast cancer respectively176. Additional findings were that the proportion of  patients with 
detectable ctDNA and the ctDNA concentrations increased with stage. These data demonstrate 
that ctDNA is present in a large proportion of  patients with this tumour types in stages I-III and 
this may thus be a useful diagnostic test for early detection of  disease. 
A recent advancement is the development of  a blood-based screening test for CRC, which uses 
the methylated septin 9 gene (SEPT9) in plasma as a biomarker: this assay has been reported to 
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specifically identify the majority of  CRCs of  all sites and stages178. Septin 9 protein plays an essential 
role in pseudopod protrusion, tumour cell migration and invasion, and it has been shown that a 
region in its promoter is methylated in CRC. In malignancies with a viral aetiology, viral circulating 
nucleic acids could be employed for screening: circulating EBV DNA was used to diagnose early 
nasopharyngeal carcinoma179.  
 
2.5. Circulating tumour DNA in pancreatic adenocarcinoma 
Yamada et al. were the first to detect circulating DNA harbouring cancer-specific somatic 
mutations in the plasma of  patients with PDAC in 1998180. However, there are few studies in the 
literature concerning the analysis of  ctDNA with the new, highly sensitive methodologies 
mentioned above in pancreatic cancer. Compared to other malignancies, PDAC has a momentous 
advantage when it comes to genetic alterations to be tested for in a liquid biopsy. More than 90% 
of  pancreatic adenocarcinomas harbour mutations in the KRAS gene as founder mutations; as a 
result, detectable mutant KRAS fragments in cfDNA extracted from PDAC patients’ blood imply 
the presence of  circulating DNA originating from the tumour. Four point mutations, G12D, G12R, 
G12V, and G13D, account for 90% of  all KRAS mutations in pancreatic cancer181. Consequently, 
it would not be strictly necessary to identify tumour-specific mutations in various oncogenes via 
molecular analysis of  a biopsy specimen prior to ctDNA analysis, but the examination of  a very 
limited number of  mutations in one gene in a liquid biopsy would be sufficient. However, the 
concordance between mutations observed in cfDNA with those seen in PDAC tumour tissue is 
still to be conclusively determined.  
The previously cited multi-disease study by Bettegowda et al.176 included 155 patients with 
pancreatic cancer. The investigators reported the detection of  ctDNA in approximately 85% of  
patients with advanced pancreatic cancer (n = 34) and 48% of  patients with localised pancreatic 
cancer. 
Earl et al.182 examined cfDNA concentration and KRAS mutation detection in 31 patients with 
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PDAC. Despite using Droplet Digital PCR, one of  the most sensitive technologies available, only 
8 out of  31 (26%) patients had detectable mutant KRAS in cfDNA. These included 3 patients with 
resectable disease, one with LAPC and 4 with mPDAC. However, ctDNA KRAS positivity strongly 
correlated with overall survival in this study (60 days for KRAS mutation positive patients vs. 772 
for KRAS-negative patients; hazard ratio for death 12.2, 95% CI 3.3-45.1, p < 0.001). 
Sausen et al.183 used digital PCR alongside with NGS of  tumour tissue to identify cancer-specific 
mutations in 51 patients with resectable PDAC, largely focusing on alterations in the KRAS gene. 
The presence of  ctDNA in plasma was demonstrated in 22 patients (43%), a similar proportion to 
the one reported by Bettegowda and co-workers. Specificity was > 99.9%. These findings suggest 
that a substantial proportion of  early-stage PDACs could be diagnosed with this noninvasive 
method. The presence of  ctDNA at diagnosis was predictive of  disease recurrence (p = 0.015, log-
rank test). Liquid biopsy was also repeated at several time points following resective surgery, 
revealing that patients with detectable ctDNA after surgery had a higher risk of  relapse, compared 
to those with liquid biopsy negative for ctDNA (p = 0.02, log-rank test). The detection of  ctDNA 
in plasma anticipated radiological determination of  progression by an average of  6.5 months (3.1 
months vs. 9.6 months after surgery, p < 0.001, paired t-test). These further results indicate that 
ctDNA analysis could be a highly performing test to monitor residual disease after resection and 
allow early detection of  relapse. 
The largest study investigating ctDNA in pancreatic cancer, which analysed blood samples from 
259 patients, was published by Takai et al.181 in 2015. Mutant KRAS was detected by Droplet Digital 
PCR in the plasma of 58.9% of patients with stage IV disease, 18.2% of LAPC patients, and 8.3% 
of patient with resectable disease. The proportion of ctDNA in total cfDNA ranged between 0 to 
87.7%. Among the 9 KRAS-positive patients who underwent resection, 5 patients relapsed within 
6 months after surgery, and had a poor prognosis. The authors suggested that patients with 
borderline resectable PDAC and mutated KRAS gene detected in plasma might be spared the risk 
of upfront surgery and be offered neoadjuvant chemotherapy. Multivariate analysis showed the 
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presence of mutant KRAS in plasma to be an independent negative prognostic factor for overall 
survival. The NGS Illumina method was subsequently used, finding comparable mutant KRAS 
frequencies. The investigators proposed that the reason why only a minority of patients with stage 
I-III pancreatic cancer had detectable mutant KRAS in plasma could be that PDAC is a 
hypovascular tumour and, therefore, little tumour DNA is released into the circulation as long as 
the disease is localised. Other authors claimed that the amount of  wild-type stromal DNA released 
from the mass into the bloodstream could have a great impact on the relative amount of mutant 
circulating DNA184. Another reason might be that Droplet Digital PCR could not detect ctDNA 
because of the low quantity of template DNA in the small volume of plasma available for analysis; 
it may be possible to detect early-stage PDAC via liquid biopsy by using a larger volume of plasma 
(approximately 5 ml in the studies by Bettegowda et al.176 and Sausen et al.183).  
Kinugasa et al.185 examined two cohorts of patients with pancreatic cancer. In the first one, 
KRAS mutations were determined both in EUS-FNA specimens and in cfDNA. KRAS mutations 
were detected in 74.7% of  the tissue samples, while the percentage of  patients with mutant KRAS 
in serum as determined by Droplet Digital PCR was 62.6%. The most frequently found mutation 
was G12D (38.6%), followed by G12V (34.6%) and G12R (5.3%). The concordance rate of  KRAS 
mutations between EUS-FNA tissue specimens and ctDNA was 77.3%. In the second group, 
mutant KRAS ctDNA was detectable in 54.5% of  patients. In both cohorts, Kaplan-Meier analysis 
demonstrated that median survival was significantly lower in patients with mutant KRAS ctDNA 
detectable (413 vs. 276 and 489 vs. 186 days respectively, p < 0.02), this aspect being particularly 
evident in the case of  the G12V mutation. The authors speculated that ctDNA analysis could have 
the potential to become both a diagnostic and prognostic marker in pancreatic cancer. This study 
also used 20 individuals with chronic pancreatitis as controls; 4 subjects had detectable mutant 
KRAS in the absence of  any evidence of  pancreatic cancer. The presence of  the mutated gene in 
cfDNA is likely to be transient and to originate from hyperplastic cells in the chronically inflamed 
pancreas. This finding is consistent with two other works, implying that mutant KRAS is not 100% 
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specific for PDAC184. 
Zill et al.186 analysed ctDNA in blood compared to tumour biopsy samples in 17 patients with 
localised and advanced pancreatobiliary cancers. 90.3% of  mutations detected in tumour biopsies 
were also found in cfDNA using NGS techniques. Assuming molecular analysis of  the tissue 
biopsy as the gold standard, the diagnostic accuracy of  cfDNA sequencing was 97.7%, with 92.3% 
average sensitivity and 100% specificity across five genetic determinants. The most commonly 
mutated genes were KRAS and TP53. Another aim of  this was to test a correlation between 
dynamic changes in the mutant ctDNA proportion in cfDNA and disease course; eight patients 
were monitored with serial liquid biopsies and the conventional marker CA19.9 was determined 
concurrently. The mutant ctDNA proportion for the most prevalent mutation was compared to 
the CA19.9 concentration for each patient. The direction of  change in CA19.9 and ctDNA 
percentage agreed significantly more often than by chance (p = 0.02). Moreover, changes over time 
in the ctDNA fraction of  cfDNA correlated well with changes in CA19.9 (Pearson’s r = 0.69 for 
interval slopes, r = 0.93 for interval differences). This finding suggests that ctDNA fraction 
changes reflect variations in tumour load during treatment in pancreatobiliary cancers.  
Notably, all of  the cited studies have been published within two years from the present time. 
These first data would classify ctDNA as a promising method for use as a liquid biopsy in 
pancreatic cancer.  
ctDNA liquid biopsy could play a role in many different stages of  pancreatic cancer 
management. Of  note, obtaining a suitable tumour tissue specimen in pancreatic cancer is 
particularly problematic (up to 30% of  biopsies are inadequate for diagnosis: QNS, quantity not 
sufficient, or TND, tumour not detected). This is because the anatomic position of  the pancreas 
makes the procedure quite invasive, patients are often highly symptomatic and with a poor 
performance status, and neoplasms contain a high proportion of  desmoplastic stroma187.  
Being able to use a simple peripheral blood sample instead would therefore be very appealing 
for diagnosis, given the minimal invasivity and the substantially lower costs, compared to EUS-
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FNA: approximately US$50 vs. US$1405188. Also, histological examination and molecular analysis 
of  a tissue biopsy are lengthy processes, while it only takes about 15 hours from receiving the 
plasma sample to obtaining final data using ctDNA analysis with Droplet Digital PCR181. Patients 
whose general conditions are too poor to undergo invasive tests, or those in which the results of 
the biopsy were inconclusive, would be the ones to benefit most from the liquid biopsy. However, 
in order to be implemented as a diagnostic tool, the capability of  the liquid biopsy to detect ctDNA 
both in early-stage and advanced PDAC has to be definitively cleared187.  
ctDNA could be used to monitor patients after surgery: the findings of  Sausen and co-
investigators183 about the opportunity to identify patients with residual disease and early detect 
relapse with the liquid biopsy need to be replicated in larger studies. In the future, it might be worth 
doing to look at whether initiating chemotherapy just after “liquid biopsy relapse” instead of  
waiting after radiological recurrence could have any clinical benefit187. 
In pancreatic cancer, assessing the efficacy of chemotherapy by CT or MR imaging is particularly 
difficult, because of the dense fibrotic tissue surrounding the tumour. Therapeutic decisions are, 
therefore, made taking into account CA19.9 levels. Theoretically, ctDNA could be used as a marker 
of  response to treatment and disease progression detection just like CA19.9. However, there is 
little evidence for such an approach in patients with PDAC187. The majority of  studies up to present 
day included a small number of  patient and only collected a single blood sample to supplement 
data provided by molecular analysis of  a tumour tissue specimen at diagnosis. To the best of  the 
author’s knowledge, the only work in which patients were prospectively followed-up with ctDNA 
interrogation during chemotherapy for locally advanced or metastatic PDAC is a small trial 
published earlier this year by Tjensvoll et al.189. In this study, plasma samples were collected from 
14 patients prior to the initiation of  treatment and subsequently every month during treatment. A 
peptide-nucleic-acide-clamp PCR was employed to detect KRAS mutations. The median follow-
up time was 3.7 months (range 0.6-12.9 months). At baseline, 10 (71%) patients had detectable 
mutant KRAS in plasma, indicating the presence of  ctDNA. Nine out of  10 experienced 
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progression of  disease progression during follow-up, compared to only one (25%) of  the four 
ctDNA-negative patients (p = 0.01). The pre-therapy ctDNA level was a statistically significant 
predictor of  both PFS and OS (p = 0.014 and 0.010, respectively). An additional finding was that 
the ctDNA level at baseline was significantly higher in patients who experienced disease 
progression compared to patients with stable disease (p = 0.024) at follow-up. Kaplan-Meier 
survival analyses indicated trends towards shorter PFS and OS for patients who were ctDNA-
positive before the initiation of chemotherapy (p = 0.064 and p = 0.066, respectively). For 10 out 
of the 14 patients, 2 or more follow-up samples were available; generally, ctDNA levels witnessed 
substantial variations during chemotherapy, which corresponded with CA19.9 levels and 
radiological responses in 3 patients, whose clinical history was extensively described by the authors. 
Comparing ctDNA levels and radiological responses, it would appear that ctDNA analysis may 
reveal disease progression before CT/MR scans, at least in a subgroup of patients. In conclusion, 
the results of this pilot study would seem to support the hypothesis that ctDNA has the potential 
to be used as a marker for predicting response to chemotherapy and reveal disease progression in 
advanced PDAC.  
In the future, the analysis of liquid biopsies could provide a personalised genetic profile for 
patients with pancreatic cancer and identify which targeted agents could be most active. However, 
targeted therapy, with the possible exception of erlotinib, has still to be proven active in PDAC. 
Imamura et al. wrote that “for the development of the field [liquid biopsy], pancreatic 
adenocarcinoma seems to be the ideal cancer to investigate”190. However, at present, it looks like 
we are only in possess of preliminary data and a great deal of further research is needed before 
achieving high-grade evidence on this topic.  
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Chapter 3. Our study: Circulating mutant KRAS as a biomarker to monitor 
response to treatment in pancreatic cancer 
 
3.1. Rationale and aims of  the study 
At the present time, an optimal marker to monitor response to systemic treatment in advanced 
pancreatic cancer is still lacking. As a result of  the above-mentioned difficulty to assess tumour 
volumes because of  the desmoplastic stroma surrounding the tumour, the evaluation of  treatment 
response in pancreatic cancer also takes into account serum markers. CA19.9 is the only approved 
circulating tumour marker for PDAC but has various limitations, such as suboptimal sensitivity 
(79%) and specificity (82%)191. These respectively result in a significant number of  false negatives 
in the case of  early invasive PDAC or preinvasive lesions, and false positives, which can occur, for 
instance, when the biliary excretion of  the protein marker is diminished due to nonmalignant 
pathologies of  the biliary tract (e.g. choledocholithiasis, cholangitis)50. Therefore, new circulating 
biomarkers to supplement information provided by imaging are urgently needed, so as to optimally 
manage these patients and improve their clinical outcome. 
The detection of  somatic mutations in cfDNA released in plasma is tumour-specific. Several 
studies have demonstrated that the ctDNA is measurable in blood samples collected from patients 
with both early and advanced pancreatic cancer176,181–183,185,186,189. ctDNA in advanced PDAC was 
reported to be detectable in up to 60-80% patients prior to systemic treatment176,181,185,189.  
KRAS is mutated in over 90% of  PDACs; 4 point mutations, G12D, G12R, G12V, G13D 
encompass nearly all KRAS mutations in pancreatic cancer181. Thereby, we hypothesise that the 
longitudinal monitoring of  KRAS somatic mutations in plasma may be instrumental for a better 
assessment of  chemotherapy efficacy. 
 The primary endpoint of  our proof-of-concept study is to correlate the levels of  mutant KRAS 
in the plasma of  patients with advanced pancreatic adenocarcinoma with radiological response to 
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treatment. 
Secondary endpoints are to determine if  and by how long ctDNA dynamic changes can 
anticipate the clinical response and if  ctDNA positivity at baseline is predictive in terms of  
progression-free survival. 
  
3.2. Materials and methods 
 
3.2.1. Study population 
24 patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy were 
consecutively recruited at the Department of  Medical Oncology of  the Santa Chiara Pisa 
University Teaching Hospital from October 2015 to May 2016. 62 blood samples were collected 
between the beginning of  the study and August 2016.  
To be eligible, patients had to be fit for combination chemotherapy with regimens such as 
FOLFIRINOX or gemcitabine plus nab-paclitaxel. In other words, patients were required to have 
an ECOG Performance Status of  0 or 1 at the institution of  chemotherapy and have normal or 
subnormal bilirubin levels, bone marrow, hepatic and renal function. Treatment was administered 
until disease progression, unacceptable toxicity or patient refusal.  
Patients underwent standard disease monitoring by imaging according to Response Evaluation 
Criteria in Solid Tumours (RECIST) 1.1: a computed tomography (CT) or magnetic resonance 
imaging (MRI) scan of  the abdomen and chest was performed at baseline and every 8-12 weeks. 
Tumour loads at baseline and at best response were calculated by adding up the diameters (in 
millimetres) of  the RECIST 1.1 target lesions on the corresponding CT scan. Depending on the 
total, patients were classified as having or not a high subjective tumour burden, and as having a 
low, moderate or high tumour burden.  
CA19.9 levels were determined at baseline and best radiological response. Data on performance 
status, adverse events, serum chemistry and haematology and concomitant medications were 
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collected at every chemotherapy cycle. Blood samples were drawn by venipuncture prior to the first 
cycle, after 14 days, 2 months and after radiological determination of  disease progression. 
Since the analysis of  KRAS mutations in plasma is not part of  the standard clinical management 
of  PDAC, the study was submitted and approved by the Ethics Committee of  Pisa University 
Hospital and conducted in agreement with the principles of  the Declaration of  Helsinki; all 
patients gave their signed informed consent before blood collection and ctDNA analysis. 
 
3.2.2. Plasma collection and circulating cell-free DNA extraction 
Six ml of  blood were collected in an EDTA test tube and centrifuged at 4°C for 10 min at 3000 
rpm within two hours after blood drawing. Plasma samples were stored at −80°C until analysis. 
Circulating cell-free DNA was extracted using a QIAmp® Circulating nucleic acid Kit (Qiagen, 
Valencia, CA, USA) from 3 to 5 ml of  plasma.  
Free-circulating nucleic acids in biological fluids are usually bound to proteins or enveloped in 
vesicles, requiring an efficient lysis step in order to release cfDNA. Therefore, the first step for 
cfDNA extraction (Fig. 15) had to be a lysis process. Samples were lysed under highly denaturing 
conditions at elevated temperatures (60°C) in the presence of proteinase K and Buffer ACL, which 
together ensure the inactivation of plasma DNases and RNases and the complete release of nucleic 
acids from bound proteins, lipids, and vesicles192.  
In the second step, the lysate was transferred onto a QIAamp Mini column. cfDNA was 
adsorbed from the relatively large volume of lysate onto the small silica membrane of the QIAmp 
Mini column as the lysate was drawn through by the pressure applied by a vacuum pump (Fig.15). 
Binding conditions were adjusted by adding Buffer ACB to allow optimal binding of the cfDNA 
to the silica membrane; salt and pH conditions ensured that proteins and other contaminants were 
not retained on the QIAamp Mini membrane192. 
The third step was the removal of residual contaminants. cfDNA remained bound to the 
membrane, while contaminants were efficiently washed away during 3 wash steps (Fig.15)192. 
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In the fourth and final step, elution of highly pure cfDNA was performed using Buffer AVE 
(Fig. 15)192. cfDNA was eluted in 50 μl of  the elution buffer. 
 
3.2.3. Measurement of  circulating tumour DNA  
The investigational part of  this study included the detection of  the mutations in KRAS codon 
12 and 13 in cfDNA. The quantification of  ctDNA was conducted by Droplet DigitalTM PCR 
(ddPCR) using the ddPCR Mutation Assay (BioRad®, Hercules, CA, USA). The analysis was 
performed with a ddPCR KRAS Multiplex assay, and the results were validated using the single 
mutation assays for the most common variants G12D, G12V, G12R, G13D. 
ddPCR has been developed to provide high-precision, absolute quantification of  DNA: ddPCR 
can measure the number of  copies of  a target sequence per volume unit by counting the DNA 
molecules contained in discrete, volumetrically defined water-in-oil droplet partitions193. This 
technique has unparalleled sensitivity, achieved by means of  the signal-to-noise increase provided 
by the use of  droplets which, theoretically, encapsulate no more than one molecule of  target DNA 
(limiting dilution). 
The first step of  the procedure is the preparation of  a ddPCR reaction mix, in a way that is 
entirely similar to any other real-time PCR: the sample of  cfDNA previously obtained is combined 
with the ddPCR supermix, primers, DNA polymerase, and probes labelled with a FAM or HEX 
reporter fluorophore. 
Subsequently, samples are placed into a droplet generator, used to partition each sample into 
approximately 20,000 nanoliter-sized droplets uniform in volume, thus enabling precise target 
quantification. Water droplets are suspended in oil. During the partitioning process, background 
and target DNA (in our case, total cfDNA and fragments containing the KRAS gene) are 
distributed randomly into the droplets. This means that a droplet may contain no nucleic acid 
template, background DNA sequences, one target DNA sequence or a combination of  the 
previous options (Fig. 16)193. 
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A PCR amplification follows; the defining feature of  ddPCR is that thanks to the previous 
partitioning the reaction goes on independently in every single droplet. The amplification protocol 
was standardised for all mutations to the following conditions: 95°C × 10 min, 94°C × 30 s and 
55°C × 60 s (35 cycles), 98°C × 10 min, and 4°C hold.  
After the PCR reaction, a droplet reader is employed for fluorescence signal quantification. 
Droplets are analysed singularly using a two-colour detection system set to detect the fluorophores, 
FAM and HEX193. Positive droplets, containing at least one target DNA molecule, exhibit increased 
fluorescence compared to negative ones (Fig. 17A). In our reaction, FAM was associated to wild-
type KRAS, and HEX to mutant KRAS.  
Data can be viewed in a 2-D plot in which FAM fluorescence is represented on the x-axis and 
HEX fluorescence on the y-axis193. Droplets cluster into four groups: FAM-negative, HEX-
negative (double-negative droplets which did not contain a target DNA template), FAM-positive, 
HEX-negative (droplets containing wild-type KRAS), FAM-negative, HEX-positive (droplets 
containing mutant KRAS ctDNA), FAM-positive, HEX-positive (double-positive droplets 
containing both mutant and wild-type templates) (Fig. 17B). 
The QuantaSoftTM software measures the number of  positive and negative droplets for both 
fluorophores (FAM/HEX). The proportion of  positive droplets is then fitted to a Poisson 
distribution; this allows to quantify the number of  copies of  the target molecule, as copies/ml and 
fraction of  the total cfDNA initially present in the sample193.  
A fluorescence intensity threshold of  3000 was set as cut-off  value and all droplets above this 
threshold were considered as positive for mutant KRAS. Samples were deemed KRAS-positive 
when at least 3 HEX-positive droplets above the threshold level were identified. 
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3.3. Results 
 
3.3.1. Clinical features of  the study population 
Out of  the 24 patients recruited, 14 were males and 10 females. Median age was 67 years old 
(range: 48-75). The site of  the primary tumour was the head or uncinate process of  the pancreas 
in 12 patients and the body or tail of  the pancreas in the remaining 12 subjects. Three patients were 
classifiable as having stage III disease (LAPC), and 21 had stage IV disease (mPDAC) at accrual. 
In the cases in which a previous resection had been performed and pathologic staging determined, 
grading was G2 for 3 patients and G3 for 4 patients. 
Eight patients received first-line FOLFIRINOX, 15 gemcitabine plus nab-paclitaxel, and one 
patient was administered a combination of  nab-paclitaxel plus 5-FU/LV and oxaliplatin, (NAB-
FOLFOX), as part of  a phase II trial investigating the activity of  this new regimen194. 18 patients 
had an ECOG Performance Status of  0 on the administration of  the first cycle of  chemotherapy, 
while 6 were classifiable as having an ECOG PS of  1. The median number of  chemotherapy cycles 
administered was 5.5 (range 1-10). 
Best response was assessed by RECIST 1.1 criteria. The best response during follow-up was 
radiological partial response for 8 patients and stable disease for other 8 patients; unfortunately, 8 
patients showed progression of  disease at follow-up imaging.  
Median PFS was 5.9 months (range 1.8-9.0 months). 12 patients experienced disease 
progression, and 8 went on to receive second-line chemotherapy. The regimens administered for 
second-line treatment were FOLFIRINOX (1 patient), gemcitabine plus nab-paclitaxel (1 patient), 
FOLFIRI (5-FU/LV plus irinotecan, 4 patients), nab-paclitaxel monotherapy (2 patients). One out 
of  the 3 patients with LAPC received 9 cycles of  FOLFIRINOX, experienced a partial response, 
and has been deemed to be a candidate for resection by a multidisciplinary team. 
Median OS was not reached, because only 2 patients passed away during follow-up. Median 
follow-up was 6.5 months (range 1.0-10.0 months). 
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14 patients had liver metastases, 5 patients had peritoneal deposits, 4 had lung nodules, 1 had 
bone lesions, 18 did not undergo resection of  the primary tumour, and 1 had a local relapse.  
Nine patients were deemed to have a subjectively high tumour burden at baseline; 2 patients 
were found to have an objectively low tumour load, 13 a moderate tumour load and 9 a high tumour 
load at baseline.            
CA19.9 average concentration at baseline was 4140.8 U/ml (median 1038.7 U/ml, range 0.6-
20450.0 U/ml); at best response, its average was 2955.7 U/ml (median 975.2 U/ml, range 2.0-
18772.0 U/ml). CA19.9 average levels stratified by response to treatment can be found in Table 8. 
 
3.3.2. Circulating tumour DNA interrogation             
Mutant KRAS was detected in 22 patients throughout the entire follow-up of  the 24 patients 
recruited, indicating the presence of  ctDNA. The most common mutation was G12D, found in 14 
patients (58%), followed by G12V, detected in 4 patients (17%), and G12R and G13D, both present 
in 2 patients (8% each). Two patients had plasma samples persistently negative for mutant KRAS 
(Table 8).  
19 patients had detectable somatic mutations in KRAS at baseline (79%). In KRAS-positive 
samples, the average baseline amount of  ctDNA was 5030 copies/ml (median 260 copies/ml, 
range 80-64800 copies/ml). On average, KRAS-mutant ctDNA accounted for 5.41% of  total 
cfDNA (median 1.60%, range 0.08-38.60%). 22 patients had a second plasma sample available for 
analysis. After the first cycle of  chemotherapy, KRAS somatic mutations could not be detected in 
8 patients (36%), while 14 patients (63%) had measurable levels of  mutant KRAS. The average 
concentration of  ctDNA in the 14 KRAS-positive patients was 1280 copies/ml (median 240, range 
100-10900 copies/ml); ctDNA made up for an average percentage of  2.73% of  total cfDNA 
(median 1.35%, range 0.09-14.00%). 14 patients provided a third blood sample, and 4 a fourth one 
(Table 9).  
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3.3.3. Monitoring of  circulating tumour DNA levels during chemotherapy 
Longitudinal monitoring of  the levels of  KRAS somatic mutations in plasma was possible for 
22 out of  the 24 patients enrolled (91.7%). The remaining two patients were lost to follow-up due 
to disease-related complications. Other two patients provided two samples in which no ctDNA 
could be detected. Among the patients with multiple follow-up samples collected, many had 
ctDNA levels which varied considerably during the course of  chemotherapy, thus possibly allowing 
the use of  ctDNA as a biomarker for the assessment of  treatment response and early detection of  
disease progression. 
For the majority of  patients, ctDNA changes corresponded to radiological follow-up data. Out 
of  11 KRAS-positive patients who developed progressive disease, 8 had an upward trend in ctDNA 
levels; among the 9 patients who did not experience progression, 6 had a downward trend, with 
undetectable mutant KRAS in the last follow-up sample in 4 patients. However, 3 patients with 
declining mutant KRAS concentrations experienced progression, while 3 patients with no 
progression at follow-up imaging had rising levels of  ctDNA (Fig. 18). 
For instance, patient 7, a 64-year-old lady who had previously undergone surgical resection 
(pT3N0) and had developed recurrent disease in the form of  liver metastases, received 5 cycles of  
first-line FOLFIRINOX but rapidly progressed (CT scan performed at 9 weeks of  follow-up). 
This patient did not have elevated CA19.9 values. The trend for KRAS trend in this subject is 
shown in Fig. 19. After the first cycle, KRAS concentration very slightly declined from 1800 to 
1700 copies/ml, but after three months peaked at 11100 copies/ml; figures concerning the ctDNA 
to total cfDNA ratio showed a continuous upward trend from 3.5 to 3.8 and 9.9%.  
On the other hand, patient 16, a 69-year-old gentleman with unresected primary tumour and 
liver metastases, received 9 cycles of  FOLFIRINOX and experienced a partial response, confirmed 
radiologically after 9 weeks of  follow-up. CA19.9 concentrations were 5592 U/ml and 4810 U/ml 
at baseline and at response respectively. ctDNA concentration dropped from 11700 copies/ml 
(19.4% of  total cfDNA) at baseline to 900 copies/ml (3.4% of  total cfDNA) after the first cycle, 
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and further fell to 130 copies/ml (0.13%) after 3 months. The last follow-up blood sample, 
collected after 4 months of  follow-up, showed undetectable mutant KRAS (Fig. 20).  
The subgroup of  patients with no progression of  disease and a concordantly downward trend 
in ctDNA levels had substantially lower levels of  ctDNA after the first cycle of  chemotherapy; on 
average, 260 copies/ml vs. 3060 copies/ml at baseline (-91.6%), or as regards ctDNA to total 
cfDNA ratio, 0.72% vs. 5.20% (-86,1%). This marked fall anticipated the radiological response by 
an average of  54 days. 
ctDNA and CA19.9 trends were also analysed stratifying by response to treatment (Table 10). 
Patients with disease control had, on average, considerably lower KRAS levels at response (610 
copies/ml at radiological response vs. 1750 copies/ml at baseline for partial response and 160 
copies/ml at radiological response vs. 860 copies/ml at baseline for stable disease respectively). 
This was true for CA19.9 as well (1080 vs. 2170 U/ml and 1050 vs. 3060 U/ml respectively). 
Instead, considering all patients who experienced disease progression, KRAS levels were almost 
four-fold increased at progression as compared to baseline (3950 copies/ml at radiological 
progression vs. 1110 copies/ml at baseline), while CA19.9 concentrations were slightly lower (6500 
vs. 7820 U/ml).  
However, a comparison between the values of  baseline ctDNA stratified by best response did 
not achieve statistical significance (Kruskal-Wallis test with Dunn’s test for multiple comparisons, 
all p values > 0.17). Similarly, baseline values did not show a statistical difference between patients 
who encountered disease progression and patients who did not (Mann-Whitney’s test, p = 0.17).   
On the first follow-up sample (15 days after chemotherapy initiation), ctDNA levels for patients 
with disease control at the end of  the follow-up and patients who experienced disease progression 
were not statistically different (Mann-Whitney’s test, p = 0.24). For the sample collected two 
months after the start of  treatment, statistical analysis identified a marginal trend towards 
significance for the same comparison (Mann-Whitney’s test, p = 0.10).  
We analysed ctDNA level trends for patients with and without progression of  disease by using 
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a ctDNA change index, defined as ([ctDNA]t – [ctDNA]t=0)/[ctDNA]t=0, where t = 0 refers to 
baseline. Statistical analysis did not reveal a significant difference between progressing and not 
progressing patients as regards the trend indexes relative both to the sample collected 15 days after 
chemotherapy initiation (p = 0.12) and to the sample drawn 60 days after chemotherapy institution 
(p = 0.14). Patients with disease control had an average ctDNA change of  -48.8% at 15 days of  
treatment, while patients who encountered progression had an average ctDNA change of  +250.0% 
at the same time point (Fig. 21). 
We distinguished two groups of  patients according to a cut-off  of  6 months as regards PFS; 
patients who enjoyed a longer progression-free survival had an average ctDNA change of  -33.3% 
after the first chemotherapy cycle, while patients who had shorter PFS had a ctDNA change index 
of  +1754%. However, the difference was not statistically significant (p = 0.45) (Fig. 22).  
3.3.4. Correlation and survival analyses 
A correlation analysis between baseline mutant KRAS and CA19.9 levels and various clinical 
variables was carried out. None of  the correlations considering ctDNA levels achieved statistical 
significance, but three of  them showed a distinct trend towards significance. Baseline mutant KRAS 
concentrations were moderately correlated with the baseline tumour burden, calculated as the total 
of  the diameters of  RECIST 1.1 target lesions (Pearson’s r = 0.39, p = 0.06), with progression-free 
survival (Pearson’s r = -0.36, p = 0.08), and overall survival (Pearson’s r = -0.37, p = 0.06). CA19.9 
levels at baseline were moderately correlated with tumour load as well (Pearson’s r = 0.37, p = 
0.07).  
Survival analysis did not show any statistical difference between patients who were KRAS-
positive and KRAS-negative at baseline as regards progression-free survival (log-rank, Mantel-Cox 
test, p = 0.14) and overall survival (log-rank, Mantel-Cox test, p = 0.84). However, it is worth noting 
how only 1 patient out of  the 5 who were KRAS-negative at baseline experienced progression of  
disease and 4 are still progression-free, while 11 patients out of  19 with detectable ctDNA at 
baseline have progressed up to the present time (Fig. 23).  
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We also examined whether there was any difference in PFS between the groups of  patients who 
were KRAS-positive and KRAS-negative at 15 days of  treatment; statistical analysis did not confirm 
the presence of  any (log-rank test, Mantel-Cox test, p = 0.19) (Fig. 24). 
Finally, we chose to investigate whether patients who had stable or declining ctDNA after 15 
days of  treatment enjoyed a longer PFS than patients who showed an upward trend. The difference 
was statistically significant (log-rank, Mantel-Cox test p = 0.037, hazard ratio 0.05, 95% CI 0.01-
0.83) (Fig. 25). 
Post-hoc power analysis showed that the statistical power for this sample is <0.8. 
 
3.4. Discussion 
Our work is, to the best of  the author’s knowledge, the largest one investigating the possible 
use of  ctDNA as a marker of  response to treatment in advanced pancreatic cancer. When the 
recruitment started, there were no studies targeting this issue in the literature. Very recently, a paper 
which extensively deals with the chance to monitor chemotherapy efficacy with the liquid biopsy 
has been published by a Norwegian research group, Tjensvoll and colleagues from Stavanger 
University Hospital189. This study, however, was conducted on an even smaller number of  subjects 
than our own.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
Our population sample was composed of  slightly younger patients than the average for patients 
diagnosed with PDAC (67 vs. 71 years old), possibly because we selected subjects who were fit for 
the newer and more aggressive chemotherapy regimens. Half  of  our patients had a primary tumour 
in the body or tail of  the pancreas, compared to the 20% reported in the literature.  
The length of  the follow-up was higher than that of  Tjensvoll et al. (6.5 vs. 3.7 months). Our 
patients seemed to enjoy a relatively better prognosis. In fact, progression was encountered in 12 
patients out of  24 (50%), as opposed to the 11 out of  14 (79%) described by Tjensvoll and co-
workers189. Similarly, only 2 patients deceased during the follow-up (8%), compared to 10 (71%) in 
the Norwegian study. The underlying reason may be that, in the Norwegian cohort, about two-
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fifths (6/14, 42%) of  patients received gemcitabine monotherapy, whereas all our patients 
benefited from more active regimens. As a result, median OS data were not available for our cohort. 
Considering all the samples collected, we reported a higher proportion of  KRAS-positive 
patients than any other previous study (91.7%). This may be due to several factors: most studies to 
date only determined KRAS mutational status only once; we employed ddPCR, one of  the most 
sensitive methodologies available at the present time; we only recruited patients with LAPC and 
mPDAC; we did not analyse a group of  healthy controls to set a cut-off  value for KRAS mutations 
positivity, but used the arbitrary threshold of  3000 as for fluorescence intensity. It would be very 
interesting to analyse tumour biopsies from these patients and to confirm the high proportion of  
mutations in KRAS with the current gold-standard methodology of  tumour tissue molecular 
analysis. 
We mentioned that, however, only 19 patients were KRAS-positive at baseline. Three subjects 
had undetectable mutant KRAS in plasma at chemotherapy institution, but later follow-up plasma 
samples revealed measurable quantities of  ctDNA. This might be explained by the emergence of  
progressive disease during follow-up, but only one out of  the 3 patients in question encountered 
progression. As the methodology employed, ddPCR, has a sensitivity higher than 99.9%, it is 
unlikely that low concentrations of  ctDNA at baseline went missed. However, the technique is 
quite complex, and pre-analytical errors might have occurred. Molecular analysis of  tumour tissue 
could prove instrumental in these cases to clarify the mutational status of  KRAS. The issue of  
patients who are KRAS-negative at baseline but are identified as KRAS-positive during follow-up 
needs to be discussed in the future when more evidence about the mechanisms of  ctDNA shedding 
is available. 
The case of  patient 7 clearly shows how urgently a new tumour marker for monitoring of  
treatment response is needed, because this patient did not have elevated CA19.9 levels despite the 
advanced stage of  the disease. At least 10% of  Caucasian patients remain CA19.9-negative in this 
condition because of  a genetic defect in the enzyme producing the polysaccharidic antigen in 
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question50.  
The borderline significant correlation (p = 0.06) highlighted for baseline KRAS levels and 
tumour burden supports our hypothesis that the amount of  ctDNA in the blood is related to 
tumour load. Nonetheless, the range of  KRAS levels seen at baseline was extremely high: 90 to 
64800 copies/ml, or 0.08 to 38.6% of  total cfDNA. The mechanism through which pancreatic 
neoplasms release higher or lower quantities of  tumour DNA in the bloodstream needs to be 
further elucidated.  
The ranges for patients who responded and did not respond to chemotherapy were largely 
overlapping; many patients who developed progression of  disease started out with values as low as 
120 copies/ml, and in one case even with undetectable ctDNA. Intriguingly, however, the subject 
who had the highest overall concentration of  ctDNA (64800 copies/ml, 38.6% of  total cfDNA), 
patient 21, provided only one sample because she received one cycle of  gemcitabine plus nab-
paclitaxel before being lost to follow-up because of  disease-related complications. 
We could speculate that ctDNA concentration trends may be more informative than KRAS 
baseline levels. Although statistical significance was not achieved because of  our small sample size, 
in the group of  patients with disease control ctDNA levels after one cycle of  chemotherapy were 
almost halved as compared to baseline, while in the group of  patients progressing the same figure 
was increased on average 2.5-fold over the same period. 
In our cohort, we were not able to prove that dynamic changes in ctDNA levels allow to 
anticipate the radiological establishment of  progression. The reason for this probably lies with the 
fact that, in our study, blood samples were not drawn at regular time intervals, but, potentially, there 
could be quite a long time span between the sample collected after three months of  treatment and 
the one at progression. One may hypothesise that a liquid biopsy performed some weeks (or even 
months) before progression may reveal increasing levels of  mutant KRAS, thus allowing the 
clinician to predict it. However, Tjensvoll et al. pointed out that an increase in ctDNA levels could 
only be observed at the same time as imaging confirmed progression in some patients189. 
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Instead, considering a subgroup of  patients (n = 6) who responded to chemotherapy and had, 
consistently with the hypothesis that mutant KRAS may be used as a surrogate biomarker for 
tumour load, a downward trend in ctDNA levels, a considerable decline in the values was evident 
already on the second liquid biopsy, 15 days after chemotherapy institution. This means that the 
decrease in ctDNA values preceded the radiological confirmation of  response to therapy (partial 
response/stable disease) by almost two months. Remarkable drops in mutant KRAS levels after the 
first chemotherapy cycle may, therefore, be a predictive marker for a good treatment response. This 
aspect had never been pointed out in previous works. It should also be noted that patients achieving 
disease control, on average, showed a decline in ctDNA levels at 15 days of  treatment while patients 
who encountered progression had rising values; however, the comparison between the two groups 
did not achieve statistical significance. 
As regards the 6 patients with divergent ctDNA levels trends and treatment responses, it should 
be said that the case of  patients with increasing values of  mutant KRAS in the blood and no 
radiological evidence of  progression could be explained by the fact that the median follow-up time 
in our study was relatively short. A subsequent CT/MRI scan may very possibly unveil progressive 
disease, anticipated by several months by the upward trend of  ctDNA levels. Out of  the 3 patient 
who experienced progression of  disease but had declining mutant KRAS in consecutive plasma 
samples, 2 had peritoneal nodules, which may release tumour DNA into the ascitic fluid instead of  
the bloodstream. 
Many studies reported ctDNA positivity as a negative prognostic factor182,185,189. In our cohort, 
KRAS positivity at baseline and at 15 days of  treatment was not proven to have an adverse impact 
on PFS and OS. This may be correlated with the low proportion of  KRAS-negative patients we 
reported, compared to other studies, thus not allowing the achievement of  statistical significance, 
also given our small sample size and short follow-up. However, Fig. 23 clearly shows that Kaplan-
Meier curves for PFS in patients KRAS-positive and KRAS-negative at baseline do not overlap. 
Moreover, the correlation analysis identified a trend towards significance for baseline KRAS levels 
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and progression-free survival and baseline KRAS and overall survival (p = 0.08 and p = 0.06 
respectively). Thereby, we are hopeful that a longer follow-up and the recruitment of  a higher 
number of  participants may unveil a statistically significant difference. The fact that post-hoc power 
analysis indicated a statistical power inferior to 0.8 confirms that there is still room for 
improvement and our results may be regarded as preliminary. 
The finding that patients who have stable or declining ctDNA after the first cycle of  
chemotherapy have a significantly longer PFS as opposed to patients who have rising values of  
ctDNA is very intriguing, because it suggests that the early assessment of  ctDNA levels during 
chemotherapy may identify a subgroup of  patients with better prognosis.  
The limitations of  the current study are the small sample size (N = 24), the short follow-up 
time (median 6.5 months) and the fact that ctDNA levels were not regularly monitored throughout 
the entire duration of  treatment. Thereby, we aim to continue with the follow-up of  the patients 
included and to enrol others so as to at least double our sample. The newly-recruited patients will 
be drawn a blood sample on a monthly basis, as in the study by Tjensvoll and colleagues. 
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Chapter 4. Conclusions 
 
The results of  our pilot study support the hypothesis that ctDNA may be adopted as a new 
marker for monitoring treatment efficacy in advanced pancreatic cancer. We confirmed, as shown 
by some works in the literature, that ctDNA detection in patients with late-stage pancreatic cancer 
is feasible in the vast majority of  cases. Additional findings are that early changes (after 1 cycle of  
chemotherapy) in ctDNA levels could predict response to treatment and PFS and that KRAS-
negative patients at baseline may represent a subgroup with more favourable prognosis. However, 
future trials further investigating this matter under highly rigorous conditions in larger cohorts are 
warranted. 
Despite the substantial advancements achieved in recent years, the prospects of  the vast majority 
of  patients newly diagnosed with pancreatic cancer are still grim. However, much research is being 
carried out at present, and the estimates that predict PDAC to become the second cancer killer in 
the United States within the next fifteen years6 likely imply that substantial investments will be 
made in this field. A breakthrough may be on the horizon, as suggested by an editorial very recently 
appeared in The Lancet Oncology with the intriguing title “Pancreatic cancer: cause for optimism?”195.  
Two new active regimens for advanced disease have been established in the last five years, 
FOLFIRINOX102 and gemcitabine plus nab-paclitaxel103; the development of  new therapies thanks 
to large randomised clinical trials is, however, imperative. Earlier this year, positive results regarding 
two new promising adjuvant regimens were presented, gemcitabine plus capecitabine82 in Europe 
and the oral fluoropyrimidine S-181 in Japan. As regards surgical techniques, laparoscopy for distal 
pancreatectomy is being investigated as an alternative to conventional open surgery68,69, which will 
possibly allow faster recovery from surgery and earlier initiation and better toleration of adjuvant 
treatment. A number of targeted therapy agents such as mitogen-activated protein kinase 
inhibitors196 or VEGF inhibitors197,198 have been unsuccessful in prolonging patients’ survival, but 
many others are being examined in currently ongoing clinical trials. Pancreatic cancer is generally 
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regarded as resistant to immunotherapy, but initial evidence from recent studies suggests that this 
deadly malignancy might be sensitised to immunotherapy199,200. Finally, in the near future, the 
analysis of circulating tumour DNA might play a part in allowing optimal management of patients, 
thus becoming a useful instrument in the fight against the disease which was described as “the 
ruthless dictator of all cancers”1.     
The benefits of  the analysis of  circulating tumour DNA are that it is a highly specific, minimally 
invasive and relatively inexpensive test. As a consequence, the liquid biopsy is easily repeatable: the 
chance to longitudinally compare samples drawn from the same patient, thus providing real-time 
assessment of  treatment efficacy or resistance, is another major strength of  this approach.  
The basis of  the high specificity of  ctDNA analysis is the fact that the somatic mutations found 
in circulating DNA derive from the neoplasm, and these mutations are an exquisite feature of  
malignant cells. As regards sensitivity, research carried out in different cancers have demonstrated 
that ctDNA is detectable in most patients with advanced disease176. Previous works found 
detectable ctDNA levels in 25-85% of  PDAC patients176,182,183,185. Our study found an even higher 
percentage of  KRAS-positive patients with advanced pancreatic adenocarcinoma.  
There are many potential applications of  this technique, such as monitoring of  tumour load and 
treatment response, identification of  genetic determinants for therapy, assessment of  tumour 
heterogeneity and resistance to targeted therapy, monitoring of  minimal residual disease and early 
detection of  cancer.  
Pancreatic adenocarcinoma has been defined as the ideal disease in which liquid biopsy may 
prove useful190. Anatomical and clinical factors make it particularly difficult to obtain tumour tissue 
specimens; the current serum biomarker, CA19.9, is not sufficiently sensitive and specific. A very 
limited number of  point mutations in a single oncogene, KRAS, act as founder genetic alterations 
in almost all PDACs; as a result, mutant KRAS has been the subject of  the majority of  studies 
targeting ctDNA in pancreatic cancer. The tumour suppressor genes CDKN2A, TP53, and 
SMAD4 are mutated in more than half  of  PDACs. Thereby, it has been hypothesised that 
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employing an expanded panel of  somatic mutations to include alterations in these genes alongside 
with KRAS mutations could further increase the proportion of  ctDNA-positive patients and 
provide additional information189.  
However, there are still many open issues to address before ctDNA can undergo clinical 
implementation. The liquid biopsy needs to be validated as a biomarker in large prospective studies 
with a statistically powerful sample size in which blood samples are collected on a regular basis 
throughout treatment; the results obtained will have to be correlated with clinical variables129. In 
these studies, a comparison between ctDNA, conventional markers and imaging should be 
performed; a ctDNA threshold value for clinical relevance, as for every biomarker, is required. 
Another matter is the lack of  consensus on which is the most efficient approach for the 
quantification and analysis of  ctDNA. Such methodologies are still in a developmental stage; 
several steps of  the process such as blood collection, processing, storage, DNA extraction and 
quantification, and target molecules need to be standardised to obtain a high volume of  comparable 
data129,190.  
Quite a lot about the dynamics of  ctDNA shedding is still unknown. A number of  variables, 
such as tumour size, site of  lesions, and systemic treatment could impact on ctDNA release. The 
timing of  molecular monitoring in connection with therapy, in particular, may play a substantial 
role. A high amount of  ctDNA could be released into the bloodstream following chemotherapy 
due to massive cancer cell death; a blood sample drawn during or immediately after treatment 
administration could also reveal various allelic fractions of  ctDNA129.   
There is another serious issue to be tackled. Even if  an increase in ctDNA levels was proven to 
be highly predictive of  disease progression, the appropriate management of  a patient showing such 
a trend remains to be determined. It may be appropriate to analyse ctDNA after each chemotherapy 
cycle, trying to determine a cut-off  point after which patients should be randomised to switch 
chemotherapy regimen for “liquid biopsy progression” or carry on with the same regimen until 
radiological confirmation of  progression, and compare survival rates. Nonetheless, there is little 
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point in proving that a patient is not responding to treatment a greater number of  effective 
treatments for pancreatic cancer are available187.   
Our pilot study, similarly to that by Tjensvoll et al.189, provides preliminary evidence supporting 
ctDNA utilisation as a marker of  response to systemic treatment and progression in advanced 
pancreatic cancer. At the moment, there are no available studies in which ctDNA was used to 
diagnose pancreatic cancer; only a small trial looked into its employment as a tumour marker in the 
adjuvant setting183. Therefore, these potential applications should be the subject of  future research.  
By way of  a conclusion, the liquid biopsy holds great promise, but a significant amount of  
further data is needed before this methodology can enter routine clinical activity. 
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Tables 
 
Table 1. Frequency of  signs and symptoms at presentation. Modified from Porta et al., 2005 
(Ref. 29, table 2). 
 
 
Symptoms 
 
Frequency 
Asthenia 86% 
Weight loss 85% 
Anorexia 83% 
Abdominal pain 79% 
Choluria 58% 
Nausea 51% 
Back pain 49% 
Diarrhoea 44% 
Vomiting 33% 
Pruritus 32% 
Steatorrhea 25% 
 
Signs 
 
 
Frequency 
Jaundice 55% 
Hepatomegaly 30% 
Upper abdomen mass 15% 
Cachexia 13% 
Courvoisier’s sign 13% 
Ascites 5% 
Thrombophlebitis 3% 
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Table 2. TNM classification for pancreatic cancer according to AJCC VII edition. Modified from 
Edge and Compton, 2010 (Ref. 54). 
 
 
Primary tumour (T) 
Tx: Primary tumour cannot be assessed 
T0: No evidence of  primary tumour 
T1: Tumour limited to the pancreas, ≤2 cm in greatest dimension 
T2: Tumour limited to the pancreas, ≥2 cm in greatest dimension 
T3: Tumour extends beyond the pancreas but without involvement of  the celiac axis or the superior 
mesenteric artery 
 
T4: Tumour involves the celiac axis or the superior mesenteric artery (unresectable primary tumour) 
 
Regional lymph nodes (N) 
NX: Regional lymph nodes cannot be assessed 
N0: No regional lymph node metastasis 
N1: Regional lymph node metastasis  
 
Distant metastasis (M) 
M0: No distant metastasis 
M1: Distant metastasis 
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Table 3.  Staging according to TNM classification, 5-year survival rate, proportion of  cases at 
diagnosis and equivalent stage according to clinical NCCN classification. Modified from Edge 
and Compton, 2010 (Ref. 54). 
  
 
Staging T N M 
5-year 
survival 
% cases at 
presentation 
Clinical 
staging 
0 Tis N0 M0 
20-25% 10-20% Resectable 
IA T1 N0 M0 
IB T2 N0 M0 
IIA T3 N0 M0 
IIB 
T1 
T2 
T3 
N1 
N1 
N1 
M0 
M0 
M0 
III T4 Any N M0 8% 25-35% 
Locally 
advanced 
(LAPC) 
IV Any T Any N M1 2% 45-55% Metastatic 
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Table 4. Criteria defining tumour resectability status, according to NCCN Guidelines, version 
2.2015. Modified from Conroy et al., 2016 (Ref. 87, table 1). 
 
 
Resectability 
status 
Arterial involvement Venous involvement 
Resectable     No contact with the celiac axis 
(CA), superior mesenteric artery 
(SMA) or common hepatic artery 
(CHA). 
    No contact with the superior 
mesenteric vein (SMV), portal vein (PV) 
or contact ≤180° without contour 
irregularity. 
Borderline 
resectable 
 Solid tumour in contact with 
CHA without extension to CA or 
hepatic artery bifurcation allowing 
for safe and complete resection and 
reconstruction. 
 Solid tumour contact with the 
CA or SMA ≤180°. 
 Solid tumour in contact >180° with 
the SMV or PV, or in contact ≤180° with 
contour irregularity of  the vein or 
thrombosis of  the vein but with suitable 
vessels proximal and distal to the site of  
involvement allowing for safe and 
complete resection and vein 
reconstruction. 
 Solid tumour in contact with the 
inferior vena cava. 
Unresectable  Solid tumour contact with SMA 
or CA >180°. 
 Aortic involvement. 
    Unreconstructible SMV/PV due to 
tumour involvement or occlusion (can be 
due to tumour or bland thrombus).  
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Table 5. Comparison of  conventional biopsy and liquid biopsy. Modified from McLarty and Yeh, 
2015 (Ref. 137, table 1). 
 
 
Key features Tissue biopsy Liquid biopsy 
Invasiveness Yes Minimal 
Sample availability 
throughout the disease course 
No Yes 
Sample stability ex vivo Stable when processed Yes 
Utility for longitudinal 
disease monitoring 
No Yes 
Cost High Low 
Processing time 
Long (involvement of  tissue 
sectioning, staining and 
pathologists) 
Short 
Failure rate 
High (quantity not 
sufficient/tumour not identified) 
Low 
Selection bias due to intra-
tumoral and inter-metastatic 
heterogeneity 
Yes No 
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Table 6. Potential clinical applications of  liquid biopsy. Modified from Diaz and Bardelli, 2014, 
and Francis and Stein, 2015 (Ref.  135, table 1; Ref. 136, table 1). 
 
 
Diagnostic marker 
    Early detection 
    Monitoring of  minimal residual disease 
Prognostic marker 
    Identification of  high risk of  recurrence 
    Correlation with changes in tumour load 
    Estimation of  survival 
Predictive marker 
    Identification of  genetic determinants for targeted 
therapy 
    Real-time assessment of  tumour heterogeneity and 
development of  resistance  
    Early evaluation of  treatment response 
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Table 7. Clinical features of  the study population. ChT, chemotherapy, FOLFIRINOX, 5-
fluorouracil, folinic acid, irinotecan, and oxaliplatin, GEM/NAB, gemcitabine plus nab-paclitaxel, 
NAB-FOLFOX, nab-paclitaxel plus 5-fluorouracil, folinic acid, and oxaliplatin, PS, Performance 
Status, PR, Partial Response, SD, Stable Disease, PD, Progression of  Disease.  
 
 
Gender M 14 pts F 10 pts  
Age Median 67 y.o. Range 48-75 y.o.  
Site of  primary 
tumour 
Head/uncinate 
process 12 pts 
Body/tail 12 pts  
Staging Stage III 3 pts Stage IV 21 pts  
Grading 
Pathological staging 
available in 7 pts 
G2 3 pts G3 4 pts 
ChT regimen FOLFIRINOX 8 pts GEM/NAB 15 pts NAB-FOLFOX 1 pt 
Performance Status at 
1st cycle 
PS 0 18 pts PS 1 6 pts  
Number of  ChT 
cycles administered 
Average 5.5 Range 1-10  
Best Response PR 8 pts SD 8 pts PD 8 pts 
Progression-Free 
Survival 
Median 5.9 months Range 1.8-9.0 months 
PD 12 pts, 
2nd line ChT 8 pts 
Overall Survival Median not reached Range 1.0-9.9 months 2 pts deceased 
Follow-up Median 6.5 months Range  1.0-10.0 months  
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Table 8. Average CA19.9 levels stratified by treatment response. PR, partial response, SD, stable 
disease, PD, progression of  disease. 
  
 
Average CA19.9 concentrations Baseline  [U/ml] Response [U/ml] 
Best response PR group 2165.8 1080.4 
Best response SD group 2713.3 1023.5 
Best response PD group 7543.2 6503.5 
All patients with disease control 2439.5 1045.4 
All patients with progression of  
disease 
5823.6 4599.0 
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Table 9. Results of  ctDNA measurements. WT, wild type KRAS, meaning mutant KRAS 
undetectable, PD, progression of  disease. 
 
Patient  
Baseline 
sample 
15 days 
sample 
60 days 
sample 
PD 
radiological 
confirmation 
sample 
PD 
1 copies/ml 260 600   YES 
 ctDNA/total cfDNA 1.4% 2.3%    
2 copies/ml WT 160 510  NO 
 ctDNA/total cfDNA WT 0.5% 1.0%   
3 copies/ml 130 3400   YES 
 ctDNA/total cfDNA 0.6% 8.6%    
4 copies/ml 220 110 WT 23800 YES 
 ctDNA/total cfDNA 1.2% 0.3% WT 28.4%  
5 copies/ml WT WT   NO 
 ctDNA/total cfDNA WT WT    
6 copies/ml 120 WT 220  YES 
 ctDNA/total cfDNA 0.2% WT 1.1%   
7 copies/ml 1800 1700 11100  YES 
 ctDNA/total cfDNA 3.5% 3.8% 9.9%   
8 copies/ml 210 140 WT  NO 
 ctDNA/total cfDNA 1.0% 0.4% WT   
9 copies/ml WT 10900 600 1200 YES 
 ctDNA/total cfDNA WT 14.0% 0.3% 1.0%  
10 copies/ml 2500 WT   NO 
 ctDNA/total cfDNA 3.8% WT    
11 copies/ml 500 190   NO 
 ctDNA/total cfDNA 2.3% 0.2%    
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12 copies/ml 120 WT 210  NO 
 ctDNA/total cfDNA 0.5% WT  1.0%   
13 copies/ml 80 WT WT  NO 
 ctDNA/total cfDNA 1.7% WT WT   
14 copies/ml WT WT   NO 
 ctDNA/total cfDNA WT WT    
15 copies/ml 50000 420 190 240 YES 
 ctDNA/total cfDNA 9.7% 1.4% 1.0% 0.6%  
16 copies/ml 11700 900 130 WT NO 
 ctDNA/total cfDNA 19.4% 3.4% 0.1% WT  
17 copies/ml 240 245 2700  YES 
 ctDNA/total cfDNA 1.6% 1.6% 1.9%   
18 copies/ml WT WT 350  NO 
 ctDNA/total cfDNA WT WT 1.5%   
19 copies/ml 3900 240 170  YES 
 ctDNA/total cfDNA 12.5% 1.3% 0.6%   
20 copies/ml 90    NO 
 ctDNA/total cfDNA 0.8%     
21 copies/ml 64800    YES 
 ctDNA/total cfDNA 38.60%     
22 copies/ml 400 100   YES 
 ctDNA/total cfDNA 0.1% 0.1%    
23 copies/ml 3300 310 90  NO 
 ctDNA/total cfDNA 3.3% 0.4% 0.8%   
24 copies/ml 150 WT   YES 
 ctDNA/total cfDNA 0.6% WT    
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Table 10. Circulating tumour DNA and CA19.9 trends stratified by treatment response. PR, 
partial response, SD, stable disease, PD, progression of  disease. 
 
 
Number 
of  patients 
KRAS at 
baseline 
[copies/ml] 
KRAS at 
response 
[copies/ml] 
CA19.9 at 
baseline 
[U/ml]  
CA19.9 at 
response 
[U/ml] 
Best response 
PR 
8 1750 610 2170 1080 
Best response 
SD 
8 860 160 3060 1050 
PD 12 1110 3950 7820 6500 
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Figures 
 
 
 
 
Figure 1. Estimated new cancer diagnoses and deaths in the United States in 2016: the ten leading 
malignancies. Modified from Siegel et al., 2016 (Ref. 5, fig.1). 
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Figure 2. Deaths due to top cancer killers in 2010 and estimates for 2020 and 2030 in the United 
States: pancreatic cancer will overcome breast and colorectal cancer and will rank second after lung 
cancer. Modified from Rahib et al., 2014 (Ref. 6, fig.1).  
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Figure 3. (A) Progression model for invasive pancreatic ductal adenocarcinoma (PDAC): acinar-to-
ductal metaplasia (ADM), pancreatic intraepithelial neoplasia (PanIN), and intraductal papillary 
mucinous neoplasia (IPMN). Modified from Neuzillet et al., 2014 (Ref. 13, fig. 1). (B) Stages of  PanIN 
and associated mutations in oncogenes and tumour suppressor genes. Modified from Muniraj et al., 2013 
(Ref. 4, fig. 13). 
 
B 
A 
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Figure 4. The multiple influences of  KRAS on the malignant PDAC cell and the possible targets for 
anti-KRAS inhibitors. Modified from Bryant et al., 2014 (Ref. 20, fig.4).
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Figure 5. Site of  pancreatic cancer and clinical presentation. Modified from Muniraj et al., 2013 (Ref. 4, 
fig. 16). 
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Figure 6. (A) Transabdominal ultrasound (AUS): hypoechoic lesion (arrows) in the head of  the 
pancreas. (B) Multidetector-row CT: low-density mass, invading celiac artery and stomach. (C) 
PET-CT: 18FDG uptake in the tail of  the pancreas. (D) Gadolinium-enhanced MRI: hypointensity 
mass (arrows) in the tail of  the pancreas. (E) Magnetic resonance cholangiopancreatography 
(MRCP): stenosis of  the main pancreatic duct with proximal dilation. (F) Endoscopic ultrasound 
(EUS): hypoechoic mass in the body of  the pancreas. Modified from Kamisawa et al., 2016 (Ref. 
33, fig. 3 and fig. 4).  
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Figure 7. NCCN clinical staging system: pancreatic cancers are classified on a continuum from 
resectable to unresectable according to the involvement of  adjacent structures and the presence of  
distant metastases. Modified from Ryan et al., 2014 (Ref. 2, fig.3). 
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Figure 8. PRODIGE4/ACCORD11 trial: Kaplan-Meier estimates of  Progression-Free Survival (PFS) 
and Overall Survival (OS) for patients with metastatic pancreatic cancer treated with first-line 
FOLFIRINOX and gemcitabine. Modified from Conroy et al., 2011 (Ref. 102, fig. 1). 
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Fig. 9. PRODIGE4/ACCORD11 trial: Kaplan-Meier curves for time until definitive deterioration 
(decrease of  20 points in the global health status/quality of  life score of  the EORTC QLQ-C30 
questionnaire) for patients with metastatic pancreatic cancer treated with first-line FOLFIRINOX and 
gemcitabine. Modified from Gourgou-Bourgade, 2013 (Ref. 105, fig.2).  
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Figure 10. MPACT trial: Kaplan-Meier estimates of  Progression-Free Survival (PFS) and Overall 
Survival (OS) for patients with metastatic pancreatic cancer treated with first-line gemcitabine plus 
nab-paclitaxel and gemcitabine alone. Modified from von Hoff  et al., 2013 (Ref. 103, fig. 1).  
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Figure 11. Release of circulating tumour DNA (ctDNA) into the bloodstream. Modified from 
Diaz and Bardelli, 2014 (Ref. 135, fig. 2). 
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Figure 12. Methodologies for the analysis of tumour DNA, relative sensitivity and optimal 
application. PCR, polymerase chain reaction; ARMS, amplification refractory mutation system; 
BEAMing, beads, emulsion, amplification, and magnetics; PAP, pyrophosphorolysis-activated 
polymerisation; TAM-Seq, tagged-amplicon deep sequencing. Modified from Diaz and Bardelli, 
2014 (Ref. 135, fig. 1). 
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Figure 13. Real-time monitoring of resistance to targeted therapy with liquid biopsy. A patient is 
diagnosed with colorectal cancer; a tissue biopsy is performed and tumour DNA is analysed. The 
tumour is found to be APC mutant and KRAS wild type. At baseline, the liquid biopsy only 
identifies wild-type KRAS fragments. The patient undergoes therapy with an anti–epidermal 
growth factor receptor (EGFR) monoclonal antibody, experiences a clinical response, and has a 
corresponding decrease in APC mutation level in circulating cell-free DNA, further indicating a 
decline in tumour burden. After some months, dynamic monitoring of circulating tumour DNA 
(ctDNA) shows detectable KRAS mutations, implying the emergence of resistant clones. 
Progression of disease is only confirmed at a later time point. Test tubes represent samples of 
plasma on which ctDNA analysis is performed. Modified from Diaz and Bardelli, 2014 (Ref. 135, 
fig. 3).  
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Figure 14. Monitoring of  minimal residual disease with liquid biopsy. A patient with breast cancer 
undergoes curative-intent resection. After surgery, the patient has no evidence of  disease; 
increasing levels of  circulating tumour DNA (ctDNA) are detected in subsequent liquid biopsies, 
possibly long before relapse manifests itself  clinically and radiologically. ctDNA analysis after 
resection could be helpful to identify patients at high-risk of  recurrence who can benefit from 
adjuvant treatment. Modified from Heitzer et al., 2014 (Ref. 130, fig. 2). 
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Figure 15. Extraction of  circulating cell-free DNA from plasma. Modified from QIAmp® 
Circulating nucleic acid Kit Handbook, 2011 (Ref. 191, fig. 1). 
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Figure 16. Partitioning in Droplet Digital PCR (ddPCR): a sample is divided into approximately 
20,000 droplets all uniform in size and volume. Target and background DNA are distributed 
randomly into the droplets, meaning that each of  them may contain no DNA sequence, 
background DNA, the target DNA sequence, or a combination of  the previous ones. Modified 
from Droplet DigitalTM applications guide, 2014 (Ref. 192, fig.1.3. and 1.4.). 
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Figure 17. (A) Droplets are spaced out individually for fluorescence reading by the droplet reader. 
Positive droplets, which contain at least one copy of  the target DNA molecule, exhibit increased 
fluorescence compared to negative droplets. (B) In a 2-D plot representing droplet fluorescence, 
droplets cluster into four groups: FAM-negative, HEX-negative (double negative droplets; bottom 
left-hand corner), FAM-positive, HEX-negative (droplets containing wild-type KRAS, bottom 
right-hand corner), FAM-negative, HEX-positive (droplets containing mutant KRAS, top left-hand 
corner), FAM-positive, HEX-positive (double-positive droplets). Modified from Droplet 
DigitalTM PCR Applications Guide, 2014 (Ref. 192, fig. 1.8. and 1.10.). 
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Figure 18. Circulating tumour DNA (ctDNA) trends for patients achieving disease control at the 
end of  follow-up and patients encountering disease progression. A consistent trend was defined as 
an upward trend for patients experiencing progression of  disease or a downward trend for patients 
with disease control. On the other hand, divergent trends were upward for patients with no 
evidence of  progression at the end of  follow-up, or downward for patients with radiological 
confirmation of  progression during follow-up. 
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Figure 19. Circulating tumour DNA (ctDNA) trend in patient 7. (A) ctDNA levels gradually but 
continuously rise reaching a peak approximately at the same time as imaging confirms progression. 
cfDNA, circulating cell-free DNA, PD, progression of  disease. CA19.9 levels are not shown 
because this patient did not have elevated CA19.9 concentrations. (B) The 2-D plots generated 
after ddPCR analysis illustrates that ctDNA levels are quite low at baseline, somewhat increased 
after 2 months of  treatment and very high in the following follow-up sample. 
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CA 19.9  Date Value 
Baseline 02/03/2016 5592 
Response 10/05/2016 4810 
 
 
 
 
 
Figure 20. Circulating tumour DNA (ctDNA) and CA19.9 trends in patient 16. (A) A remarkable 
decline in ctDNA levels anticipated radiological confirmation of  objective tumour response (PR, 
partial response) by more than 6 weeks. (B) The dynamic range of  ctDNA was by far greater than 
that of  CA19.9. (C) The 2-D plots generated by ddPCR clearly show how a relatively high baseline 
concentration of  ctDNA dramatically declines in the subsequent follow-up samples, until no 
mutant KRAS droplets can be detected. 
  
0%
5%
10%
15%
20%
25%
0 20 40 60 80 100 120 140
c
tD
N
A
/
c
fD
N
A
 [
%
]
Follow up [days]
Patient 16
CT scan, day 63
PR
C 
A 
B 
  
127 
 
 
Figure 21. Patients who achieved disease control (left column) had ctDNA levels approximately 
halving (-48.8%) over the first chemotherapy cycle; patients who experienced progression had an 
average increase of  250.0% over the same time span.  Error bars indicate the standard error of  the 
mean. Statistical comparison, however, was non-significant (p = 0.12). 
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Figure 22. The graph shows that patients having a shorter PFS had, on average, a positive ctDNA 
variation index after 15 days from the initiation of  chemotherapy, while patients with a longer PFS 
tended to have declining ctDNA levels. Error bars indicate the standard error of  the mean, which 
is remarkably high for patients with a PFS shorter than 6 months. Statistical comparison was non-
significant.  
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Figure 23. Kaplan-Meier curves for progression-free survival (PFS) in mutant KRAS-positive 
(KRAS+) and KRAS-negative (KRAS-) patients at baseline. Although the two curves clearly do 
not overlap (median PFS for KRAS+ patients, 5.9 months; median PFS for KRAS- patients, not 
reached), the sample size is too small to achieve statistical significance (HR 0,375, 95% CI 0.10 to 
1.38, p = 0.14). 
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Figure 24. Kaplan-Meier curves for progression-free survival (PFS) in mutant KRAS-positive 
(KRAS+) and KRAS-negative (KRAS-) patients after one cycle of  chemotherapy. Statistical 
analysis did not unveil a significant difference in PFS between the two groups (median PFS for 
KRAS- patients, 7.2 months; median PFS for KRAS+ patients, 2.8 months; p = 0.19). 
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Figure 25. Kaplan-Meier curves for progression-free survival (PFS) in patients who had stable or 
declining ctDNA levels after one cycle of  chemotherapy and subjects who showed an upward trend 
in ctDNA at the same time point. The median PFS for patients with stable or reduced ctDNA was 
7.2 months, while it was 2.6 months for patients with increased ctDNA; statistical analysis unveiled 
a significant difference in PFS between the two groups (HR 0.05, 95% CI 0.01 to 0.83, p = 0.037). 
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